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CONCLUSION

In many areas of innovation, the United States is a leader, but this
characterization does not apply to the United States' position in assisted reproductive
technology innovation and clinical use. This article uses a political science concept, the
idea of the "democratic deficit" to examine the lack of American public discourse on
innovations in ART. In doing so, the article focuses on America's missing public
consultation in health care innovation. This missing discourse is significant, as political
and ethical considerations may impact regulatory decisions. Thus, to the extent that
these considerations are influencing the decisions of federal agency employees, namely
those who work within the U.S. Food and Drug Administration, the public is unable to
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participate in the decision-making process. This lack of a public discourse undermines
the goals of the administrative state, which include democratic participation,
transparency, and accountability.
The United Kingdom, on the other hand, has had a markedly divergent
experience with assisted reproductive technology innovation. Instead of ignoring the
various ethical, social, and legal issues surrounding assisted reproductive technology
innovation, the United Kingdom engaged in a jive-strand public consultation on the
topic of mitochondrial transfer, a form of assisted reproductive technology that uses
genetic modification in order to prevent disease transmission. This article argues that
after a multi-decade standstill in terms of the public discourse related to ethical issues
associated with assisted reproductive technology and germline modification, it is time
for the United States to institute a more democratic inquiry into the scientific, ethical,
and social implications of new forms of assisted reproductive technology and ultimately,
forthcoming medical innovations that involve genetic modification.

INTRODUCTION
The 2010 Nobel Prize in Physiology or Medicine was awarded to Robert G.
Edwards "for the development of in vitro fertilization." 1 In awarding the prize, the Nobel
Committee noted that Dr. Edwards' "achievements have made it possible to treat
infertility, a medical condition afflicting a large proportion of humanity including more
than 10 percent of all couples worldwide." 2 Since the birth of the first child using in
vitro fertilization (a form of assisted reproductive technology) in 19783 in the United
Kingdom, various strides have been made in assisted reproductive technology. Yet while
the United States has been a leader in many domains of technological innovation and
regulation, the same characterization does not apply to the United States' place in
assisted reproductive technology ("ART").4 Most recently, forms of ART involving
genetic modifications have been developed in both the United Kingdom and the United
States.5 A number of media and scientific publications have noted that the United States
I.

t Assistant Professor, William & Mary Law School; J.D., Columbia Law School;
A.B., Harvard College. For helpful comments and suggestions, I would like to thank Aaron-Andrew Bruh!,
Evan Criddle, Tara Grove, Lisa Ikemoto, Allison Orr Larsen, Sonia Suter, and participants at the 2019
American Journal of Law and Medicine Symposium.
1
Press Release, The Nobel Assembly at Karolinska Institutet, The Nobel Prize in Physiology or Medicine
2010
(Oct.
4,
2010),,
https://www.nobelprize.org/prizes/medicine/2010/press-release/
[https://perma.cc/CK2M-NNJE].
2 Id.
3
See Genelle Weule, First IVF Baby's 40th Birthday: How a Tiny Girl Changed Science and the World, ABC
NEWS (July 24, 2018), https://www.abc.net.au/news/science/2018-07-25/first-ivf-baby-louise-joy-brown
tums-40/10017032 [perma.cc/BK2Y-XAAY].
4
For example, Professor Daniel Carpenter has observed that "the United States still houses the strongest of
global pharmaceutical regulators" after being the first such regulator in the world. DANIEL P. CARPENTER,
REPUTATION AND POWER: ORGANIZATIONAL IMAGE AND PHARMACEUTICAL REGULATION AT THE FDA 42
(2010).
5
See Myrisha S. Lewis, How Subterranean Regulation Hinders Innovation in Assisted Reproductive
Technology, 39 CARDOZO L. REV. 1239, 1242-44, 1247-51 (2018) [hereinafter Subterranean Regulation].
While the first child to be born using mitochondrial transfer was purportedly born in Ukraine, because there
is no system of regulation in Ukraine, that country is not a subject of the comparative analysis in this Article.
See Susan Scutti, Controversial IVF Technique Produces a Baby Girl - and for Some, That's a Problem, CNN
(Jan. 18, 2017), https://www.cnn.com/2017/01/18/health/ivf-three-parent-baby-girl-ukraine-bn/index.html
[https://perma.cc/DV2J-4CKH]; see also infra Part III (discussing U.S. and U.K. innovation in assisted
reproductive technology).
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will lag behind the United Kingdom in ART development due to regulatory barriers that
prevent the approval of a new form of ART, mitochondrial transfer, which combines in
vitro fertilization with genetic modification in order to prevent the transmission of
genetic disease.6
Newer forms of ART, such as mitochondrial transfer and cytoplasmic transfer,
another form of ART used in the late 1990s that also combined traditional ART with
genetic modification (also referred to as "advanced assisted reproductive technologies"),
raise interesting federalism issues: the U.S. Food and Drug Administration ("FDA") has
asserted jurisdiction over these forms of ART, meanwhile state law governs the practice
of medicine and family formation.7 This article will examine the regulation of
mitochondrial transfer in the United States and the United Kingdom, as well as the
regulation of an earlier, similar technique of ART, cytoplasmic transfer. 8 Research on
that technique in the United States has been suspended since at least 2001, when the
FDA sent letters threatening legal action to physicians researching the technique. 9 The
FD A's assertion of jurisdiction over in vitro fertilization ("IVF") practice in 2001, which
is usually the subject of state regulation, had a negative impact on research and clinical
use of other IVF techniques, including mitochondrial transfer. 10 Also, by not addressing
the safety and ethical issues related to cytoplasmic transfer in 2002, the United States
6

Nina Bai, Three- Parent Babies: The Science of Replacing Mitochondrial DNA and What Remains Unknown,
UCSF NEWS CENTER (Jan. 17, 2017), https://www.ucsf.edu/news/2017/0 l/405486/three-parent-babies
science-replacing-mitochondrial-dna-and-what-remains-unknown [perma.cc/8NCV-UBUU]; Steve Connor,
Three- Parent Baby Pioneer: "The Brits Will be Ahead of the World'", THE INDEPENDENT (Jan. 17, 2015) ('"At
least the Brits get it. They will be ahead of the world. It's too bad it's taken so long. It could have been done
15 years ago. I put my toe in the water and got shark bite, so I'm done with it. It's too bad because it cramps
creativity, it inhibits medical progress."') (quoting Dr. Jamie Grifo, and American researcher whose work on
"three-parent in vitro fertilization" was halted by the U.S. Food & Drug Admin.); Mitochondrial Donation
Treatment, HUMAN FERTILISATION & EMBRYOLOGY AUTH., https://www.hfea.gov.uk/treatments/embryo
testing-and-treatments-for-disease/mitochondrial-donation-treatment/
[https://perma.cc/2AR8-MQDE].
"Three-parent in vitro fertilization'' is the colloquial term for mitochondrial donation, which is also referred
to as mitochondrial transfer, or mitochondrial donation therapy. See HUMAN FERTILISATION & EMBRYOLOGY
AUTH., SCIENTIFIC REVIEW OF IBE SAFETY AND EFFICACY OF MEIBODS TO AVOID MITOCHONDRIAL
DISEASE
THROUGH
ASSISTED
CONCEPTION:
2016
UPDATE
42,
57
(2016),
https://www.hfea.gov.uk/media/26l l/fourth_scientific_review_mitochondria_20l6.pdf.
7 For more on federalism, see Nicholas Bagley, Federalism and the End ofObamacare, 127 YALE L.J. FORUM
1, 2 (2017); Timothy Zick, Are the States Sovereign?, 83 WASH. U. L. Q. 229, 255, 292-94 (2005). For more
on newer forms of ART, see Myrisha S. Lewis, Halted Innovation: The Expansion of Federal Jurisdiction
Over Medicine and the Human Body, 2018 UTAH L. REV. 1073, l lOO (2018) [hereinafter Halted Innovation];
Subterranean Regulation, supra note 5, at 1241-45, 1248 ("A cell essentially contains three parts: cytoplasm,
nucleus, and mitochondria. The nucleus, which is the center of the cell, is surrounded by cytoplasm.
Mitochondria are located in the cytoplasm of the cell." (citations omitted)). Mitochondrial transfer and
cytoplasmic transfer, two teclmiques of assisted reproductive technology, involve the modification of less than
.0001 percent of DNA; however, the modification of DNA (even though it is not the "nuclear DNA" that
dictates hair color and eye color for example), has led to opposition to the techniques. Mitochondrial transfer
is currently being used to prevent the transmission of genetic disease whereas cytoplasmic transfer was used
to improve fertility outcomes. Infra Part III.A
8
Connor, supra note 6; see Don P. Wolf et al., Mitochondrial Replacement Therapy in Reproductive Medicine,
21 TRENDS IN MOLECULAR MED. 68, 72 (2015) ("In 1998-1999, cytoplasmic transfer, or the augmentation of
patient eggs with a small volume (1-5%) of donor cytoplasm was used by several IVF clinics in an effort to
overcome repeated IVF failures in selected patients. The procedure essentially involved co-injection of donor
cytoplasm with sperm, as an extension of [intracytoplasmic sperm injection]. Several pregnancies were
established before the US FDA, for regulatory purposes, insisted that an investigational new drug application
be filed before the success or failure of this approach could be determined.").
9
See Subterranean Regulation, supra note 5, at 1259-62.
10
See id. at 1256, 1259-62 (discussing the "chilling effects" of the FDA's method of regulation on advanced
assisted reproductive technologies including cytoplasmic transfer and mitochondrial donation).
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fell further behind in the race towards the clinical use of mitochondrial transfer as a
number of safety and ethical issues overlap between cytoplasmic transfer and
mitochondrial transfer.11 Instead, U.S.-based physicians and patients have been driven
to reproductive tourism where they provide these techniques in countries with less
restrictive regulation. 12 Thus, those opposed to the type of work involving mitochondrial
transfer have succeeded in halting the use of the technique in the United States, whereas
institutional structures in the United Kingdom have thoroughly considered the ethical
and legal issues surrounding the use of the technique before ultimately approving it. 13
This article applies a comparative analysis to ART innovation before
concluding that the United States should undertake a public consultation related to ART
innovation similar to the United Kingdom. The political science subfield of comparative
politics has often focused on the European Union's purported "democratic deficit,"
which some have blamed for the U.K. 's vote to leave the E.U. 14 While there is no
standard definition of the "democratic deficit," generally, when a national or
supranational body suffers from a "democratic deficit," that body lacks public
accountability, transparency, and public engagement. 15 As explained infra, the United
Kingdom's approach to this technique was to eventually legalize it after an extensive
public consultation, whereas the United States' approach has been to use administrative
law to hinder the use of this technology, and a preceding but similar technology,
cytoplasmic transfer, without having any public discourse on the social, ethical, and
political considerations implicated by the technique. 16
This article contributes to the health law, family law, innovation law, and
administrative law literatures. In health law and family law, there is a significant (and
Id. at 1271-79.
See sources cited infra note 117 and accompanying text discussing the work of Dr. Jolm Zhang, a U.S.
based physician, in Mexico; infra notes 195,199 discussing reproductive and medical tourism.
13
See infra Part III; see also Doctors Given Approval for UK's First 'Three- Person Babies', BBC NEWS (Feb.
11

12

2,2018),https://www.bbc.com/news/health-42918341 [https://perma.cc/U92N-LTEE].
14
See K.K. DuVivier, The United States as a Democratic Ideal? International Lessons in Referendum
Democracy, 79 TEMP. L. REV. 821, 855 n. 245 (2006); R. Daniel Kelemen, Europe's Other Democratic
Deficit: National Authoritarianism in Europe's Democratic Union, 52 Gov'T & OPPOSITION 211, 211 ("For
years, many scholars of European integration have argued that the EU suffers from a democratic deficit,due
to the lack of public engagement and political accountability at the EU level and the absence of a common
public sphere or common demos characteristic of national democracies."); id. at 211 n.l; Stephen C.
Sieberson, The Proposed European Union Constitution - Will it Eliminate the E U's Democratic Deficit?, 10
COLUM. J. EUR. L. 173,174 (2004); id. at 195 ('"Democratic deficit . . . refers to the legitimacy problems of
non-majoritarian institutions,i.e.,institutions which by design are not directly accountable to the voters or to
their elected representatives."' (citing Giandomenico Majone, Europe's 'Democratic Deficit': The Question
of Standards, 4 EUR. L.J. 5,15 (1998)).
15
See Andreas Follesdal & Simon Hix, Why There is a Democratic Deficit in the E U: A Response to Majone
and Moravcsik, 44 J. COMMON MKT. STUD. 533,534 (2006) ("There is no single meaning of the 'democratic
deficit'. Definitions are as varied as the nationality, intellectual positions and preferred solutions of the
scholars or commentators who write on the subject. Making a similar observation in the mid-1990s, Joseph
Weiler and his colleagues set out what they called a 'standard version' of the democratic deficit."); 534-36
(providing five elements of a "standard version " of the democratic deficit: "First, and foremost, European
integration has meant an increase in executive power and a decrease in national parliamentary control..
Second, and related to the first element, most analysts of the democratic deficit argue that the European
Parliament is too weak. . . . Third, despite the growing power of the European Parliament, there are no
'European' elections. . . . Fourth, even if the European Parliament's power were increased and genuine
European elections were able to be held, another problem is that the EU is simply 'too distant' from voters .
. Fifth, European integration produces 'policy drift' from voters' ideal policy preferences."); Peter L.
Lindseth,Democratic Legitimacy and the Administrative Character of Supranationalism: The Example of the
European Community, 99 COLUM. L. REV. 628,657,684 (1999).
16
See Subterranean Regulation, supra note 5,at 1241-45; infra Part III;.
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often overlapping) literature addressing ART innovation and the consequences of using
ART. 17 The article simultaneously contributes to the health law and administrative law
literatures by revealing how the operation of administrative law may be hindering
innovation in medicine. 18 More specifically,, the article contributes a specific subset of
the "health-care administrative law" literature surrounding ART and innovative
therapies by using the concept of "democratic deficit," a political science concept, to
illustrate a lack of transparency and public participation in the regulation of innovations
in ART. 19 Moreover, from the perspective of innovation and technology governance, the
divergent experiences of the United States and the United Kingdom on advanced
assisted reproductive technologies indicates that, in the realm of advanced assisted
reproductive technology, the general approach to risk where, "for example Europe tends
to give greater prominence to precaution while the United States assigns a stronger role
to liability" is reversed.20 Due to the role of administrative institutions in the analysis,
the article also implicates comparative administrative law and comparative health law.2 1

17
See Michele Goodwin, Prosecuting the Womb, 76 GEO. WASH. L. REV. 1657, 1693 (2008); Alexander N.
Hecht, The Wild Wild West: InadequateRegulation of Assisted Reproductive Technology, 1 HOUS. J. HEALTH
L. &POL'Y 227, 228 (2001); see also NAOMIR. CAHN, TEST TuBEFAMILIES: WHY THE FERTILITY MARKET
NEEDS LEGAL REGULATION vii, 1-10 (2009); DEBORA L. SPAR, THE BABY BUSINESS: How MONEY, SCIENCE,
AND POLITICS DRIVE THE COMMERCE OF CONCEPTION 5 (2006); Courtney M. Cahill, The Oedipus Hex:
Regulating Family After Marriage Equality, 49 U.C. DAVIS L. REV. 183 (2015); Naomi R. Chan & Jennifer
M. Collins, Eight is Enough, 103 NW. U. L. COLLOQUY 501, 507 (2009); Judith F. Daar, Regulating
Reproductive Technologies: Panacea or Paper Tiger?, 34 HOUS. L. REV. 609, 615 (1997) ("[Assisted
reproductive technology] is subject to little formal regulation"); Marsha Garrison, Regulating Reproduction,
76 GEO. WASH. L. REV. 1623 (2008); Hank Greely, Cloning and Government Regulation, 53 HASTINGS L.J.
1085, 1089-90 (2002); Kathryn V. Lorio, The Process of Regulating Assisted Reproductive Technologies:
What We Can Learn from Our Neighbors- What Translates and What Does Not, 45 LOY. L. REV. 247, 247
(1999); Kimberly M. Mutcherson, Blood and Water in a Post- Coital World, 49 FAM. L. Q. 117, 127 (2015);
Lars Noah, Assisted Reproductive Technologies and the Pitfalls of Unregulated Biomedical Innovation, 55
FLA. L. REV. 603, 614-15 (2003); Gaia Bernstein, Regulating Reproductive Technologies: Timing,
Uncertainty, and Donor Anonymity, 90 B.U. L. REV. 1189, 1196-1205 (2010); June Carbone & Paige
Gottheim, Markets, Subsidies, Regulation, and Trust: Building Ethical Understandings into the Market for
Fertility Services, 9 J. GENDER RACE & JUST. 509, 511 (2006) ("The regulation offertility services involves
the creation ofnorms about a new and rapidly growing technology.).
18
See Timothy S. Jost, Health Law and Administrative Law: A Marriage Most Convenient, 49 ST. LOUIS U.
L. J. 1, 14-16, 29 (2004); infra Part LB.
19
See, e.g., Daniel A Farber & Anne J. O'Connell, The Lost World of Administrative Law, 92 TEX. L. REV.
1137, 1137 (2014) (identifying administrative law's goals as "transparency, rule of law, and reasoned
implementation of statutory mandates"); Emily Hammond & David L. Markell, Administrative Proxies for
Judicial Review: Building Legitimacy from the Inside-Out, 37 HARV. ENVTL. L. REV. 313, 316 (2013)
(identifying "administrative law values of participation, deliberation, and transparency, which guard against
arbitrariness and foster accountability"); Jost, supra note 18, at 1 (referring to the concept of "health-care
administrative law"); id. at 9-14; Michael A Livermore, Political Parties and PresidentialOversight, 67 ALA.
L. REV. 45, 110 (2015); Robert Rohrschneider, The Democracy Deficit and Mass Support for an EU- Wide
Government, 46 AM. J. OF POLI. SCI. 463, 463 (2002); Miriam Seifter, Second-Order Participation in
Administrative Law, 63 UCLA L. REV. 1300, 1302 (2016) ("[P]ublic participation is a cornerstone of
administrative law.")
20
Gary Marchant, Resilience: A New Tool in the Risk Governance Toolbox for Emerging Technologies, 51
U.C. DAVIS L. REV. 233, 245 (2017).
21
See Francesca Biguami, From Expert Administration to Accountability Network: A New Paradigm for
Comparative Administrative Law, 59 AM. J. COMP. L. 859, 860 (2011) ("Comparative administrative law ..
seeks to uncover the similarities and differences that mark multiple legal systems."); Susan Rose-Ackerman,
Comparative Administrative Law: Outlining a Field of Study, 28 WINDSOR Y.B. ACCESS JUST. 435, 436
(2010). For more on comparative health law, see generally Diane Hoffmann, Comparative Health Law and
Policy: What, IfAnything, Can We Learn fromOther Countries?, 37 J.L. MED. & ETHICS 790 (2009).
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Ultimately, the lessons from this project may be useful for or extrapolated to other
regimes.22
The article proceeds as follows. In part II, the article provides background
information on ART and the concept of the democratic deficit. In part III, the article
provides an overview of the regulatory systems governing innovation in and the use of
ART in the United States and the United Kingdom, with an emphasis on the two
countries' disparate regulatory approaches to traditional and newer forms of ART
involving genetic modification. Part IV uses the comparative and domestic legal
analyses from part III to explore the implications of the United States' approach to ART
regulation on innovation in the United States, including the existence of a democratic
deficit in ART innovation and use in the United States. Part V prescribes a potential
process of public consultation for the U.S., based on the U.K. 's five-strand consultation
on mitochondrial transfer, before concluding.
II.

SCIENTIFIC AND CONCEPTUAL BACKGROUND
This part provides background in the areas of political science and ART.
Section A describes the broader concept of ART, with an emphasis on IVF before
describing "advanced assisted reproductive technologies" which are forms of ART
involving genetic modification that are distinct from gene editing, another innovation
that has received significant media attention lately.23 Section B offers an overview of
the concept of "democratic deficit."
A.

ASSISTED REPRODUCTIVE TECHNOLOGY

The term "ART" can have many definitions depending on the purposes for
which the term is being used. ART is a broad field that "usually involves in vitro

See Sandy Ong, Singapore Could Become the Second Country to Legalize Mitochondrial Replacement
Therapy, SCIENCE (Jun. 6, 2018), http://www.sciencemag.org/news/2018/06/singapore-could-become
second-country-legalize-mitochondrial-replacement-therapy [https://perma.cc/BTY2-PMSX]; Scientists Say
it's Time to Make '3- Parent Baby' Technology Legal in Canada, CBC RADIO (Mar. 26, 2018),

22

https://www.cbc.ca/radio/quirks/march-24-2018-an-alien-looking-skeleton-three-parent-families-in-canada
and-more-l .4588650/scientists-say-it-s-time-to-make-3-parent-baby-technology-legal-in-canada-l .4588671
[https://perma.cc/ZN5R-SZ4C] (providing comment of Health Canada on possible legal changes to
accommodate new forms of assisted reproductive technology, "Health Canada is the federal authority
responsible for administering and enforcing the Assisted Human Reproduction (AHR) Act. The AHR Act
prohibits a person from knowingly altering the genome of a cell of a human being or in vitro embryo such that
the alteration is capable of being transmitted to descendants. Genome is defined in the AHR Act as the totality
of the deoxyribonucleic acid (DNA) sequence of a particular cell. Since mitochondrial replacement therapy
involves the introduction of mitochondrial DNA from a third party and since the introduced DNA is capable
of being inherited by the resulting embryo,a person performing this procedure in Canada would be violating
a provision of the AHR Act. . . . After the current regulatory project is complete,the Department will consider
the need to amend the Assisted Human Reproduction (AHR) Act to reflect advances in science that have taken
place since the Act was first enacted in 2004. This will include revisiting the prohibition in the Act that
currently makes it illegal in Canada for a person to conduct mitochondrial replacement therapy (MRT). Health
Canada recognizes the promise that the application of this technology, and other technologies that create
heritable changes to the genome, may hold. However, further consideration is required, including whether
changes to the prohibitions would continue to reflect the values of Canadians, before such changes could be
contemplated.").
23
See Subterranean Regulation, supra note 5,at 1241. This Article focuses on forms of assisted reproductive
technology involving genetic modification such as mitochondrial transfer and cytoplasmic transfer,although
as will be explained in Parts III and IV,the lessons from this Article,which addresses medical techniques that
are accompanied by ethical controversy, could eventually be relevant in similar studies of gene editing
technologies. This Article focuses on assisted reproductive technology involving heritable genetic
modifications, and while there are some aspects of it that are similar to gene editing (and many that are not),
comparative aspects of the regulation of gene editing will be the focus of a subsequent Article.
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fertilization," where "an egg is removed from [a] woman's ovary and fertilized with [a]
man's sperm in a petri dish" in a laboratory setting. 24 "If fertilization occurs, the resulting
embryo is" implanted into a woman's utems. 25 In the United States, the Centers for
Disease Control and Prevention ("CDC"), which is part of the U.S. Department of
Health and Human Services ("HHS"), explains the term as
" .. .includ[ing] all fertility treatments in which both eggs and embryos
are handled. In general, ART procedures involve surgically removing
eggs from a woman's ovaries, combining them with sperm in the
laboratory, and returning them to the woman's body or donating them to
another woman. They do NOT include treatments in which only sperm
are handled (i.e., intrauterine-or artificial-insemination) or
procedures in which a woman takes medicine only to stimulate egg
production without the intention of having eggs retrieved." 26
The CDC's definition of ART draws on the only federal statute that is clearly applicable
to ART, the 1992 Fertility Clinic Success Rate Act.27 Other operating divisions of the
HHS use similar definitions, as do the National Academies of Science, Engineering, and
Medicine, Society for Assisted Reproductive Technology, and American College of
Obstetricians and Gynecologists.28 In the United Kingdom, the Human Fertilisation and
Embryology Authority, National Health Service, and the UK's National Institute for
Health and Care Excellence use similar definitions of ART (also referred to as "assisted
conception") and "fertility treatment," as the CDC.29
Lori B. Andrews & Lisa Douglass, Alternative Reproduction, 65 S. CAL. L. REV. 623, 631 (1991); see
Frequently Asked Questions: Gynecologic Problems, AM. COLLEGE OF OBSTETRICIANS & GYNECOLOGISTS
(Oct.
2017),
https://www.acog.org/Patients/FAQs/Treating-Infertility?IsMobileSet=false#assisted
[https://perma.cc/V9ZY-R8XC]. For an overview of the mechanics of in vitro fertilization, see John A
Robertson, Embryos, Families, and Procreative Liberty: The Legal Structure of the New Reproduction, 59 S.
CAL. L. REV. 939, 944-52 (1986).
25
Andrews & Douglass, supra note 24, at 631; see Lars Noah, Assisted Reproductive Technologies and the
Pitfalls of Unregulated Biomedical Innovation, 55 FLA. L. REV. 603, 608 (2003) (characterizing in vitro
fertilization as "represent[ing] the paradigmatic form of ART").
26
What is Assisted Reproductive Technology?, CTRS. FOR DISEASE CONTROL & PREVENTION (Feb. 7, 2017),
https://www.cdc.gov/art/whatis.html [https://perma.cc/Q5B7-W25L].
27
Id.; see 42 U.S.C. §§ 201, 263a-l -a-7 (2012); Yaniv Heled, The Regulation of Genetic Aspects of Donated
Reproductive Tissue-The Need for Federal Regulation, 11 COLUMBIA SCI. & TECH. L. REV. 243, 250-51
(discussing the Fertility Clinic Success Rate Act of 1992); Jamie King, Predicting Probability: Regulating the
Future of Preimplantation Genetic Screening, 2 YALE J. HEALTH LAW, POL'Y, & ETHICS 101, 153 (2008)
(noting that "[o]verall, the CDC has very limited power over ART clinics. [The Fertility Clinic Success Rate
Act] specifically states that the "Secretary [of the Department of Health and Human Services] may not
establish any regulation, standard or requirement which has the effect of exercising supervision or control over
the practice of medicine in ART programs.").
28See NAT'L RESEARCH COUNCIL, SCIENTIFIC AND MEDICAL ASPECTS OF HUMAN REPRODUCTNE CLONING
61 (2002); Assisted Reproductive Technology, NAT'L CANCER INSTIT. DICTIONARY OF GENETICS TERMS,
https://www.cancer.gov/publications/dictionaries/ genetics-dictionary/def/assisted-reproductive-technology
[https://perma.cc/GA6B-9N3L] ("A term used to describe collectively a number of noncoital methods of
conception that are used to treat infertility with donor or nondonor eggs and sperm including in vitro
fertilization (IVF), gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT). Also
called ART."); Assisted Reproductive Technologies, SOC'Y FOR ASSISTED REPRODUCTIVE TECH.,
https://www.sart.org/topics/topics-index/assisted-reproductive-technologies/ [https://perma.cc/SFT2-V8SC].
29
NAT'L HEALTH SERV., CLINICAL COMMISSIONING POLICY: ASSISTED CONCEPTION, REFERENCE, 2014, : N
SC/037, at 5-7, 9, https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/20l 4/ l l /n
sc037.pdf ("Assisted reproduction [:] The collective name for treatments designed to lead to conception by
means other than sexual intercourse. Assisted reproduction techniques include intrauterine insemination (IUI),
24
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Two techniques of ART, cytoplasmic transfer and mitochondrial transfer,
combine IVF with genetic modification by combining or substituting, respectively, the
genetic material of the sperm and eggs that would usually be used in IVF, with the
genetic material from the mitochondria or cytoplasm of a donor egg. 30 Mitochondrial
transfer, or mitochondrial donation, is a form of ART that aims to prevent the
transmission of mitochondrial disease from parent to child.3 1 There are two techniques
that are encompassed by the term "mitochondrial transfer": pronuclear transfer ("PNT")
and maternal spindle transfer ("MST").32 These two techniques are the most commonly
analyzed in contemporary media coverage of mitochondrial transfer and reports related
to approval of the techniques. 33 Cytoplasmic transfer is a form of ART that has received
less media attention lately but was a "precursor" to mitochondrial transfer.34
Cytoplasmic transfer involves IVF, where the egg of the intended mother would be
"revitalized" by the cytoplasm of a donor egg, in a technique that improved fertility
outcomes in the 1990s and early 2000s.35 As will be detailed infra in Part II, both
cytoplasmic transfer and mitochondrial transfer have been subject to FDA responses that
have had "chilling effects" on research and clinical practice.
Other than the Fertility Clinic Success Rate Act, professional organizations,
such as the American College of Obstetricians and Gynecologists and Society for
Assisted Reproductive Technology, play an important role in the regulation of
in vitro fertilisation (IVF), intracytoplasmic sperm irtjection (ICSI) and donor insemination (DI). The term
'assisted reproduction technology' (ART) is the term sometimes used to collectively describe these procedures
and inte1Ventions."); Explore Fertility Treatments, HUMAN FERTILISATION & EMBRYOLOGY AUTH. (Nov. 9,
2018),
[https://perma.cc/KH8M-DN36]
https://www.hfea.gov.uk/treatments/explore-all-treatments
(describing intrauterine insemination (IUI), in vitro fertilization, Intracytoplasmic sperm injection (ICSI),
fertility drugs, IVF options, surgical sperm extraction, surgeiy, and surrogacy); Fertility Problems: Assessment
and Treatment, Clinical Guideline [CGJ56], NAT'L INST. FOR HEALTH & CARE EXCELLENCE (Feb. 2013),
https://www.nice.org.uk/guidance/cgl56/ifp/chapter/assisted-reproduction [https://perma.cc/6CFD-4CYX]
("Assisted reproduction [:] Assisted reproduction is the name given to treatments that can help you get
pregnant without you having sexual intercourse. There are a variety of treatments, and what is suitable for you
will depend on your own circumstances. The options include: intrauterine insemination (IUI)[;] in vitro
fertilisation (IVF)[;] IVF with intracytoplasmic sperm irtjection (ICSI)[;] the use of donor sperm (donor
insemination) or eggs (egg donation). . . . Other methods of assisted reproduction called gamete intrafallopian
transfer (GIFT) or zygote intrafallopian transfer (ZIFT) are not recommended. Certain forms of assisted
reproduction (IUI, IVF, ICSI, donor insemination and egg donation) are regulated by law and their use is
controlled by the Human Fertilisation and Embiyology Authority"); How We Regulate, HUMAN
FERTILISATION
&
EMBRYOLOGY
AUTH.,
https://www.hfea.gov.uk/about-us/how-we-regulate/
[https://perma.cc/TF4S-E8BZ].
30
See Subterranean Regulation supra note 5, at 1248-49 ("A cell essentially contains three parts: cytoplasm,
nucleus, and mitochondria. The nucleus, which is the center of the cell, is
surrounded by cytoplasm. Mitochondria are located in the cytoplasm of the cell." (citations omitted)); see also
Paula Amato et al., Three- Parent IVF: Gene Replacement for the Prevention of Inherited Mitochondrial
Diseases, 101 FERTIL. STERIL. 31, 32-34 (2014).
31
For more explanation of how the various techniques of mitochondrial transfer operate, see AS. Reznichenko
et al., Mitochondrial Transfer: Implications for Assisted Reproductive Technologies, 11 APPLIED &
TRANSLATIONAL GENOMICS 40, 41-44 (2016); Tian Wang et a!., Polar Body Genome Transfer for Preventing
the Transmission of Inherited Mitochondrial Diseases, 157 CELL 1591, 1591 (2014); Wolf et al., supra note
8, at 69-71.
32 See NUFFIELD COUNCIL ON BIOETHICS, NOVEL TECHNIQUES FOR THE PREVENTION OF MITOCHONDRIAL
DNA DISORDERS: AN ETHICAL REVIEW vii, 36 (2014) ("The main difference between [maternal spindle
transfer and pronuclear transfer] is that MST uses two unfertilized eggs to reconstruct an egg with healthy
mitochondria that can be fertilized; in PNT, two early embiyos (zygotes) are used to reconstruct an embiyo
with healthy mitochondria."); Mitochondrial Donation Treatment, supra note 6.
33
See NUFFIELD COUNCIL ON BIOETHICS, supra note 32, at 34.
34 Subterranean Regulation, supra note 5, at 1248-50.
3s Id.
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reproductive technology by serving as "self-regulatory" or "peer regulatory"
organizations for physicians involved in the practice of ART.36 ART is highly regulated
in the United Kingdom, as detailed in part III.A.I, but is minimally regulated in the
United States, with the exception of forms of ART involving genetic modifications
(referred to herein as "advanced assisted reproductive technologies"), which are highly
regulated, as detailed in part III.B.1.
In 2005, the UK's Human Fertilisation and Embryology Authority granted a
license to researchers at Newcastle University to conduct mitochondrial research. 37 In
April 2010, a group of scientists at Newcastle University published a paper in the journal
Nature, providing "proof of concept" of pronuclear transfer.38 In 2009, researchers at
Oregon Health and Science University announced that they had successfully used
maternal spindle transfer in rhesus macaques. 39 However, as is detailed in part III of the
article, because the Oregon Health and Science University researchers were located in
the United States, their work has been stymied by the machinations of the administrative
state and Congressional funding restrictions. As will be emphasized in part IV of the
article, there is a lack of public participation and transparency in those machinations of
the administrative state, even though there are indications that those machinations
involve the use of political or social considerations by FDA employees, without a
statutory basis.40
B.

DEMOCRATIC DEFICIT

The term "democratic deficit" was first used in 1977 and has since occupied a
significant space in the political science literature. 41 Although there is no standard
definition of "democratic deficit," the concept of the "democratic deficit" highlights a
failure to achieve many of the goals of the American democratic state such as legitimacy,

See Robertson, supra note 24, at 1035-36 ("With adequate peer involvement, more explicit legal controls,
such as the national licensing authority suggested in the Warnock Report, need not take root in American
soil."); Jennifer L. Rosato, The Children of Art (Assisted Reproductive Technology): Should the Law Protect
Them from Harm?, 2004 UTAH L. REV. 57, 66 (2004) ("The American Society for Reproductive Medicine
(' ASRM') is the primary professional organization that oversees the field of reproductive medicine, and the
Society of Assisted Reproductive Technology ('SART'), an affiliated organization, specifically covers IVF
programs, in addition to other types of ART programs."(citations omitted)). The Institute of Medicine's
recommendation on the eventual use of mitochondrial transfer in the United States were directed at both the
FDA and "professional societies." See THE NAT'L ACADS. OF SCI., ENG'G. & MED., MITOCHONDRIAL
REPLACEMENT TECHNIQUES: ETHICAL, SOCIAL, AND POLICY CONSIDERATIONS 7, 71, 99 (2016) ("The
committee does not suggest an absolute limit on any eventual applicability of MRT to other conditions or
diseases, but rather believes FDA and relevant professional societies need to take a cautious approach, with
deliberate attention to ethical, social, and policy issues, in considering any uses of MRT beyond the primary
indication of preventing transmission of serious mtDNA disease." (emphasis added)).
37
See NUFFIELD COUNCIL ON BIOETHICS, supra note 32, at 34.
38
See id.
39
See id. at 36; see also Sabrina Tavernies, His Fertility Advance Draws Ire, N.Y. TIMES (Mar. 18, 2014).
40
See, e. g., Nina Mendelson, Disclosing "Political"Oversight of Agency Decision Making, 108 MICH L. REV.
1127, 1130-31 (2010); Subterranean Regulation, supra note 5, at 1271-74.
41
See Sanford Levinson, How the United States Constitution Contributes to the Democratic Deficit in
America, 55 DRAKE L. REV. 859, 860 (2007); Martin Nettesheim, Developing a Theory of Democracy for the
European Union, 23 BERK.ELY J. INT'L L. 358, 358-59 n. l (2005); see also Daniel T. Deacon, Administrative
Forbearance, 125 YALE L.J. 1548, 1589 (2016) ("One persistent criticism of the administrative state, and
particularly of broad delegations, is that policy is frequently formulated through allegedly less transparent
means. Less visible policymaking may lead to less accountable government." (citations omitted)).
36
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transparency, and an "equilibrium" between democracy and effectiveness. 42 I use the
term "democratic deficit" in this article to highlight the non-existence of those goals in
the regulation of ART at the federal level, which occurs through the use of administrative
law tools that do not involve notice-and-comment mlemaking or public participation.
While not all political scientists ascribe to the concept of "democratic deficit"
in the European Union, many analyses of the European Union and the United States
have examined political and legal challenges through the lens of the democratic deficit. 43
The term "democratic deficit[]" " ... first arose in debates about the legitimacy of the
European Union ("EU"), and has continued to surface in debates about the legitimacy
of the European Union and the analysis of actors in the European Union." 44 Most
recently, the Brexit vote has been analyzed as a response to the "democratic deficit" in
the European Union.45
As a matter of brief historical context, the European Union is characterized as
suffering from a "democratic deficit" due to its institutional structures: the Ministers of
the Council of the European Union are " ... a collectivity of nonelected civil servants"
with the authority to pass binding, enforceable legislation, without the approval of the
European Parliament, a legislative body that has been characterized as "weak." 46
See Jan Rovny, Approaches to the Democratic Deficit in the European Union, 19 PERSPECTNES: REV. OF
CENTRAL EUR. AFFAIRS 109, l l0, 113 (2003); see also sources cited supra note 19 and accompanying text
(identifying the goals of the American administrative state).
43
See PIPPA NORRIS, DEMOCRATIC DEFICIT: CRITICAL CITIZENS REVISITED 3, 5 (20 l l ) ("The gap between
aspirations and satisfaction is captured here by the concept of democratic deficits. The notion first arose in
debates about the legitimacy of the European Union (EU). The core decision-making institutions in the EU
have been regarded by some commentators as falling well short of the standards of democratic accountability
and transparency that exist at the national level within each of the member states."); Levinson, supra note 41,
at 861-62 ("There is in fact an interesting debate going on about the extent of the democratic deficit in
Europe"); id. at 862-64 (discussing the democratic deficit in the context of election law and American federal
and state constitutional law); id. at 862 n.4; Ernest A. Young, Protecting Member State Autonomy in the
European Union: Some Cautionary Tales from American Federalism, 77 N.Y.U. L. REV. 1612, 1639 (2002)
[hereinafter Protecting Member State Autonomy]; Maimon Schwarzschild, Complicated- But Not Too
Complicated: The Sunset of E. U. Law in the UK. After Brexit, 39 CARDOZOL. REV. 905, 905 n.2 (2018); see
also James Allan, Democracy, Liberalism, and Brexit, 39 CARDOZO L. REV. 879, 887-94 (2018) (discussing
"democratic deficiencies" in the context of the European Union); Ernest A. Young, What Can Europe Tell Us
About the Future of American Federalism?, 49 ARIZ. ST. L.J. l l09, 1136 (2017) [hereinafter Future of
American Federalism]; Peter Millar, What's all this about the EU's 'Democratic Deficit'?, THE GUARDIAN
(May
20,
2013),
https://www.theguardian.com/commentisfree/2013/may/20/eu-democratic-deficit.
[https://perma.cc/QXF7-PVXF].
44
See NORRIS, supra note 43, at 5; see also Andrew Moravcsik, Is There a 'Democratic Deficit' in World
Politics? A Framework for Analysis, 39 Gov'T AND OPPOSITION 336, 337 (2004) (noting that the European
Union "is widely considered to suffer from a 'democratic deficit', the redressing of which was the primary
purpose for calling the ongoing constitutional convention and negotiation."). For more on the democratic
deficit in the European Union, see J.H.H. Weiler, The Transformation of Europe, 100 YALE L.J. 2403, 2430,
2466-7, 2469 (199l i
45
See HAROLD D. CLARKE ET AL., BREXIT 72, l l4 (2017); Matthew Goodwin et al., For and Against Brexit:
A Survey Experiment of the Impact of Campaign Effects on Public Attitudes toward EU Membership, BRITISH
JOURNAL OF POLITICAL SCIENCE, at 1, 5 (2018); Samuel Issacharoff, Democracy's Deficits, 85 U. CHI. L. REV.
485, 493-94 (2018) ("In this sense, the desperate gambit of Prime Minister David Cameron [in using the
referendum on the UK's membership in the EU] . . . well follows the pattern in the European Union of seeking
to alter its perceived democratic deficit through greater use of referenda and other tools of direct democracy."
(citations omitted)); Timothy G. Ash, As an English European, This is the Biggest Defeat of my Political Life,
THE GUARDIAN (Jun. 24, 2016) (discussing "Euroskepticism").
46
Weiler, supra note 44, at 2465-68 (1991); see Overview, COUNCIL OF THE EUROPEAN UNION (Feb. 19,
2019), https://europa.eu/european-union/about-eu/institutions-bodies/council-eu_en [https://perma.cc/34AT
RF89]. While there are significant literatures in political science, comparative law, and administrative law that
analyze the European Union, this Article only analyzes the European Union in order to illustrate the concept
42
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Through structures that lack accountability, transparency, and legitimacy, such as the
Council of the European Union, which
exercise[s legislative power] 'behind closed doors' ... 'and, at a lower level, by
numerous committees of national experts, who are faceless and
unaccountable,' [through] a process [which is] 'hardly consistent with the rules
of democracy, even in the eyes of those who understand that in the formation
of legislative proposals there is limited scope for transparency.' 47
While the "democratic deficit" is a political science term that is generally
applied to analyses of the European Union, it is relevant to legal analysis, especially as
it relates to U.S. administrative law. 48 In the legal literature, the term has been used to
explore broader concerns in U.S. law, often from a comparative perspective in which
scholars explore various issues related to the Constitution of the United States and state
constitutions. 49 A lack of these democratic features leads to a democratic deficit similar
to the one that scholars attribute to the European Union's method of governance through
structures like the Council of the European Union.5° Further, methods of avoiding
democratic deficit include increasing the representation of the public in the political
system, which the American administrative state aims to do through methods of public
participation like notice-and-comment mlemaking.5 1 Nonetheless, many aspects of
federal administrative decision-making related to advanced assisted reproductive
technologies do not include public participation, as will be emphasized in part III.52
This article uses the political science concept of the "democratic deficit" to
address the lack of American public discourse on the subjects of ART and more recently,
advanced assisted reproductive technologies which involve genetic modifications in
combination ART. While America's "democratic deficit" in the realm of ART does not
have the same political consequences as the E.U. 's democratic deficit, there is no
supranational body that can impose binding legislation on the American federal
government without its approval, a democratic deficit still exists within the
administrative state. Even though the appointment of the FDA Commissioner involves
of the democratic deficit, which the Article then uses to examine the regulation of assisted reproductive
technology in the United States and United Kingdom.
Rovny,supra note 42,at l l0,113; Sieberson,supra note 14,at 195.
48
See Curtis A. Bradley,International Delegations, the Structural Constitution, and Non- Self-Execution, 55
STAN. L. REV. 1557, 1558 n.3 (2003); Levinson, supra note 41, at 860 ("The term 'democratic deficit' has
become a staple in contemporary political analysis.").
49
See Future of American Federalism, supra note 43, at l l l2 ("Finally, the Brexit vote and the parallel rise
of Euroskeptic movements in France and other Member States reflects profound popular concerns about the
legitimacy of governance at the center. Although the United States has not generally been thought to suffer
from the same sort of "democratic deficit " that haunts European discourse, we are experiencing profound
frustration with gridlocked and nonresponsive government in Washington,reflected in the precipitous decline
in public trust in national governing institutions. We are unlikely to see a 'Texit' (or perhaps more likely, a
'Utexit' or 'West Virgexit') but it is nonetheless time to ask how the eroding legitimacy of national
government may affect American federalism."(citations omitted)); Dragoljub Popovic,Prevailing of Judicial
ActivismOver Self-Restraint in the Jurisprudence of the European Court of Human Rights, 42 CREIGHTON L.
REV. 361,364 (2009) (discussing the democratic deficit in the context of unelected judges in the American
judiciary).
50
See sources cited supra note 43 (discussing the democratic deficit in the European Union with an emphasis
on the Council of the European Union).
51
Rovny,supra note 42,at l l2; see Kristin Hickman, Unpacking the Force of Law, 66 VANDERBILT L. REV.
465,520 (2013).
52
See infra Part IILB. l.
47
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both the Executive and Legislative Branches, which are both democratically accountable
to the public, the democratic deficit where " ... a collectivity of nonelected civil servants"
can incorporate social and political views into administrative agency decisions that are
not subject to public input still has significant legal and practical consequences in the
realms of access to ART due to the binding nature of many administrative agency
decisions as will be highlighted in part III.53 Examining the FDA regulation of ART
through the lens of the democratic deficit highlights how, in the context of FDA
regulation of ART, the administrative state has operated to hinder the use of advanced
assisted reproductive technologies. 54
III.

REGULATORY BACKGROUND
This article uses a comparative legal (and political) analysis to explore the
differences in the regulation of forms of ART involving genetic modification in the
United States and the United Kingdom.55 The selected case studies are countries that
have the technology to implement widespread use of mitochondrial transfer, but have
diverged in terms of the clinical use and governance of the technology. 56 Not only are
the United States and the United Kingdom two countries where the most scientific
progress in mitochondrial transfer has occurred, the countries' govermnents share some
historical and democratic commonalities.57
53
Weiler,supra note 44,at 2465-68; see James T. O'Reilly,Losing Deference in the FDA 's Second Century:
Judicial Review, Politics, and a Diminished Legacy of Expertise, 93 CORNELL L.REV. 939, 959-60 (2008)

(describing the appointment processes for the Secretary of Health and Human Services (appointed by the
President to his Cabinet) and the FDA Commissioner and other political appointees at the FDA (who are
appointed by the President and confirmed by the Senate).
54
For more on the "democratic deficit " in the context of the United Kingdom and the United States,see Future
of American Federalism, supra note 43,at 1112.
55
See Kathryn V. Lorio, The Process of Regulating Assisted Reproductive Technologies: What We Can Learn
fromOur Neighbors - What Translates and What Does Not, 45 LOY. L. REV. 247,248-49 (1999) ("Although
no one system, or any combination of systems, may be ideal for the United States to emulate, both
understanding and insight may be gained from a comparative analysis.").
56
While media reports have noted that scientists in China is making headway in the field of mitochondrial
transfer, this Article does not focus on the experience of China as it would be difficult to draw lessons from
the Chinese experience since the country is known for having a lack of regulation in the area of scientific
research. Nevertheless, China's Academy of Sciences has been involved in multiple international germline
editing summits. This Article does not explore the issue of whether mitochondrial transfer is "germline
editing." For more on the definition of the germline, see Subterranean Regulation, supra note 5,at 1249-50,
1276-78 (2018). For more on CRISPR-Cas9 gene editing in China,see Dennis Normile,CRJSPR Bombshell:
Chinese Researcher Claims to Have Created Gene- Edited Twins, SCIENCE (Nov. 26, 2018),
https://www.sciencemag.org/news/2018/ l l /crispr-bombshell-chinese-researcher-claims-have-created-gene
edited-twins [https://perma.cc/8RLP-GACW]; Sarah Zhang, Chinese Scientists are Outraged by Reports of
Gene- Edited
Babies,
Science,
THE
ATLANTIC
(Nov.
27,
2018),
https://www.theatlantic.com/science/archive/2018/l l /china-crispr-babies/576784/ [https://perma.cc/RT2J62TJ] ("China has spent billions turning itself into a scientific powerhouse, but it still struggles with the
perception that its scientists do not take ethics seriously. In 2015,when Chinese scientists raced ahead to use
CRISPR to edit genes in human embryos, an international outcry ensued.").
57
There are of course many similarities and differences between the United States and the United Kingdom,
which have been (and continue to be) studied by scholars of comparative law, institutional design, and
federalism. This Article only focuses on these similarities and differences as pertinent to the regulation of
assisted reproductive technology by the United States and United Kingdom. For background,see Steven G.
Calabresi,Does Institutional Design Make A Difference?, 109 NW. U. L. REV. 577,578 (2015) (characterizing
the United Kingdom as an "otherwise stable western constitutional democrac[y ]"); but see id. at 582-83 ("In
important respects, the U.S. federal government is far more powerful than the federal governments of the
European Union, Argentina, Brazil, Germany, India, Mexico, Canada, Australia, South Africa, and, since
devolution,the United Kingdom."); see also Martin Laffin & Alys Thomas,The United Kingdom: Federalism
in Denial?, 29 PUBLIUS 89, 90-92,106 (1999); Peter H. Schuck, Federalism, 38 CASE W. RES. J. INT'L L. 5,
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For the purposes of comparing the regulation of ART in the United States and
the United Kingdom, it is useful to note that lawmaking in the United Kingdom is also
very similar to that in the United States, although some of the terminology differs.58 Just
like in the United States, proposed legislation in the United Kingdom is called a "bill"
and final legislation in the United Kingdom is an "Act." 59 A statutory instrument is a
"type of delegated legislation," 60 which is similar to a regulation in the United States
where statutory instruments provide clarity on the meaning of various statutory terms. 6 1
Statutory instruments are normally drafted by the legal office of the relevant government
department, which is why the draft regulations related to mitochondrial transfer were
created by the UK Department of Health.62 Thus, in the realm of administrative law, the
draft regulations permitting mitochondrial transfer became a "statutory instrument" after
they were approved by Parliament.63 In the United States, relevant regulations related to
mitochondrial transfer and other forms of ART are drafted by the FDA without any sort
of legislative approval.64 This part provides background on the legal responses to various
innovations in ART in the United Kingdom and the United States.

5-6 (2006); See also Erin Ryan, Secession and Federalism in the United States: Tools for Managing Regional
Conflict in A Pluralist Society, 96 OR. L. REV. 123, 164 (2017) ()(discussing the United States' "symmetrical
federalism" and the United Kingdom's "asymmetrical federalism");
58
As noted in the preceding footnote, there are of course many differences between lawmaking in the United
States and United Kingdom; however, this paragraph (and the Article as a whole) focuses on detailing the
aspects of lawmaking in the United States and the United Kingdom that are critical to understanding the
regulation of assisted reproductive technology in both countries. Proposed legislation in the United Kingdom
is called a "bill", and an Act is the term applied to a bill that has obtained a majority vote in both the House of
Commons and House of Lords and "formal[] agree[ment] by the reigning monarch (known as Royal Assent)."
See Bills and Legislation, U.K. PARLIAMENT, http://www.parliament.uk/business/bills-and-legislation/
[https://perma.cc/A4HJ-72VJ];
House
of
Commons,
U.K.
PARLIAMENT,
http://www.parliament.uk/business/commons/ [https://perma.cc/HW6A-JUS9] ("[t]he UK public elects 650
Members of Parliament (MPs) to represent their interests and concerns in the House of Commons."); Members
and Their Roles, U.K. PARLIAMENT, http://www.parliament.uk/business/lords/whos-in-the-house-of
lords/members-and-their-roles/ [https://perma.cc/UHS8-47VP] ("Members of the House of Lords are
appointed by the Queen on the advice of the Prime Minister"); see also Stephen Gardbaum, Political Parties,
Voting Systems, and the Separation of Powers, 65 AM. J. COMP. L. 229, 230 (2017) ("When the same party
wins both the White House and Congress, the United States has 'unified' government resembling
parliamentary systems, notwithstanding the formal separation of the two branches. Only during periods of
'divided' government, where different parties control the two branches, does the Framers' conception of
institutional checks and balances--of ambition checking ambition--come close to reflecting the reality of
American politics.").
59
See sources cited supra note 58 and accompanying text.
60
What is Secondary Legislation?, U.K. PARLIAMENT, http://www.parliament.uk/about/how/laws/delegated/
[https://perma.cc/MS69-VFP2].
61
Because Acts of Parliament are often broad, "[statutory instruments] are used to provide the necessary detail
that would be too complex to include in the Act itself." HOUSE OF COMMONS INFORMATION OFFICE,
STATUTORY INSTRUMENTS 2 (2008), https://www.parliament.uk/documents/commons-information
office/107.pdf.
62
What is Secondary Legislation?, supra note 60; see Commons Debate Statutory Instrument on
Mitochondrial
Donation,
U.K.
PARLIAMENT
(Feb.
3,
2015),
http://www.parliament.uk/business/news/2015/febmary/commons-debate-statutory-instmment-on
mitochondrial-donation/ [https://perma.cc/53QC-RXS5]; see Draft Regulations on 'Three Parent' IVF
Published, NAT'L HEALTH SERV. (Feb. 28, 2014), http://www.nhs.uk/news/20l4/02Febmary/Pages/Draft
regulations-on-three-parent-IVF-published.aspx [https://perma.cc/3DMS-A78E].
63
See Commons Debate Statutory Instrument on Mitochondrial Donation, supra note 62; The Human
Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015, 2015 No. 572, THE NAT'L
ARCHIVES
(Mar.
4,
2015),
http://www.legislation.gov.uk/ukdsi/2015/9780111125816/contents
[https://perma.cc/GS5L-HUYD].
64
See PETER B. HUTT ET AL., FOOD AND DRUG LAW: CASES AND MATERIALS 1154 (4th ed. 2014).
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UNITED KINGDOM

The United Kingdom is a prominent country in terms of ART innovation. The
work of Robert Edwards and Patrick Steptoe led to the birth of the world's first baby as
a result of IVF, Louise Brown, in the United Kingdom in 1978.65 In July 1982, the
"Committee of Inquiry into Human Fertilisation and Embryology" was created. 66 The
committee's report, "the Warnock Report,"67 made 64 recommendations, 68 including
that IVF continue to be available through the National Health Service, 69 that children
conceived through IVF have the right to basic donor information including the donor's
genetic health,"70 that written consent from couples using IVF be obtained,7 1 that semen
donors not have parental rights,72 and that various constraints apply to research involving
human embryos.73 These recommendations eventually led to the creation of the UK's
Human Fertilisation & Embryology Authority and were incorporated into the United
Kingdom's regulatory framework governing the use of ART and research related to
innovation in ART.74
1.
The United Kingdom's Regulatory Framework Governing Assisted
Reproductive Technology Use and Innovation

65

The Nobel Assembly at Karolinska Institutet, supra note I.
DEP'T OF HEALTH & Soc. SEC., REPORT OF THE COMMITTEE OF INQUIRY INTO HUMAN FERTILISATION AND
EMBRYOLOGY (1984), https://www.hfea.gov.nk/media/2608/warnock-report-of-the-committee-of-inqniry
into-human-fertilisation-and-embryology-1984.pdf [hereinafter WARNOCK REPORT].
67
See WARNOCK REPORT, supra note 66. For a chapter-by-chapter summary of the Warnock Report, see
Jonathon J. LaTourelle, The Report of the Committee of Inquiry into Human Fertilisation and Embryology
(1984), by Mary Warnock and the Committee of Inquiry into Human Fertilisation and Embryology, EMBRYO
PROJECT ENCYCLOPEDIA (Oct. 2, 2014), https://embryo.asu.edu/pages/report-committee-inqniry-human
fertilisation-and-embryology-1984-mary-warnock-and-committee [https://perma.cc/BV6K-V7BN]. ).
68
WARNOCK REPORT, supra note 66, at 80-86 (providing a "List of Recommendations" related to the clinical
use of assisted reproductive technology and research on embryos).
69
Id. at 32. In the United Kingdom, health care is provided by the National Health Service, which was created
in 1948. See Robert H. Blank, The United Kingdom: Regulation Through a National Licensing Authority, in
COMPARATIVE BIOMEDICAL POLICY: GoVERNING ASSISTED REPRODUCTIVE TECHNOLOGIES 121 (2004). The
National Health Service provides free health care for UK residents. See About the NHS, NAT'L HEAL TH SERV.,
(Apr. 13, 2016), http://www.nhs.nk/NHSEngland/thenhs/about/Pages/overview.aspx [https://perma.cc/S3FB 
LD8E].
70 WARNOCK REPORT, supra note 66, at 24-25.
7 1 Id. at 25.
n Id.
73 See Mary Warnock, The Warnock Report, 291 BRIT. MED. J. 187, 187-89 (1985) (summarizing the Warnock
Report).
74 Donna M. Gitter, Am I My Brother's Keeper? The Use of Pre implantation Genetic Diagnosis to Create A
Donor of Transplantable Stem Cells for anOlder Sibling Suffering from a Genetic Disorder, 13 GEO. MASON
L. REV. 975, 987 (2006); Margaret F. Riley & Richard A. Merrill, Regulating Reproductive Genetics: A
Review of American Bioethics Commissions and Comparison to the British Human Fertilisation and
Embyology Authority, 6 COLUM. SCI. & TECH. L. REV. I, 5 (2005). While an analysis of the United Kingdom's
institutions may have required an analysis of European Union institutions and law, the United Kingdom, which
has been categorized as "experienc[ing] a rising tide of mistrust about government institutions," voted in 2016
to exit the European Union. See NORRIS, supra note 43, at 58. As such, the analysis of the U.K.'s regulatory
structure infra largely neglects the European Union's regulatory process as, as of the time that this Article is
being written, the U.K. is in the process of exiting the European Union. For more on "Brexit," see sources
cited supra note 45 and accompanying text.
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The U.K. has a robust system for regulating ART,75 which has been described
as " ... perhaps the most well-developed."76 Unlike in the United States, where traditional
ART is generally described as "minimally regulated" or "unregulated," all ART in the
United Kingdom is highly regulated.77 In contrast to the lack of regulation in the United
States (or unexpected subterranean regulation by the FDA), the United Kingdom created
a regulatory agency, the Human Fertilisation & Embryology Authority ("HFEA"),
which regulates a number of matters related to ART.78
The HFEA was authorized by the Human Fertility and Embryology Act of
199079 and "set up in 1991."80 It "is the UK's independent regulator of treatment using
eggs and sperm, and of treatment and research involving human embryos."8 1 The HFEA
describes its goals as
ensur[ing] that everyone who steps into a fertility clinic, and everyone born as
a result of treatment, receives high quality care. We do this by licensing,
monitoring and inspecting fertility clinics ... and providing free, clear and
impartial information about fertility treatment, clinics and egg, sperm and
embryo donation. We also collect data about fertility treatments. 82
These goals stem from the agency's enabling statute (in American parlance) as the 1990
Act (as amended) "gives the HFEA a number of statutory functions," including the
licensing of fertility clinics and research centers, the maintenance of a register of adverse
reactions and events and " ... regulat[ing] the storage of gametes and embryos ... "83 The
1990 version of the Human Fertilisation and Embryology Act is generally referred to as
"the 1990 Act (as amended)"; it was subsequently amended in 2008.84 The agency also
promulgates requirements related to the selection of donors of reproductive tissue. 85
Further, the HFEA also publishes a Code of Practice which it incorporates into its
75 Kerry L. Macintosh, Teaching About the Biological Clock: Age- Related Fertility Decline and Sex
Education, 22 UCLA WOMEN'S L.J. 1, 26 (2015) (citing ROBERT EDWARDS & PAlRICK SlEPTOE, A MATIER
OF LIFE: THE STORY OF A MEDICAL BREAKTHROUGH 11-15 (1980)).
76 Steve P. Calandrillo & Chryssa V. Deliganis, In Vitro Fertilization and the Law: How Legal and Regulatory
Neglect Compromised A Medical Breakthrough, 57 ARIZ. L. REV. 311, 333 (2015)
77 See Calandrillo & Deliganis, supra note 76, at 333; Subterranean Regulation, supra note 5, at 1240
("Commentators have described the regulatory environment surrounding assisted reproductive technology
[in the United States] as 'limited,' 'minimally regulated,' and even 'the Wild Wild West.' [The article] reveals,
however, that one important subset of assisted reproductive technology, the subset that contains forms of
assisted reproductive technology that combine in vitro fertilization with the modification of small amounts of
DNA . . . is an exception to this general rule." (citations omitted)).
78
About Us, HUMAN FERTILISATION & EMBRYOLOGY AUTH., https://www.hfea.gov.uk/about-us/
[https://perma.cc/B9D2-A36D].
79 Hnman Fertilisation and Embryology Act, 1990, c. 37, § 5 (Eng.).
80
Human Fertilisation and Embryology Authority Access to Anonymised Data, HUMAN FERTILISATION &
EMBRYOLOGY AUTH.
(Nov.
23
2011),
https://data.gov.uk/dataset/l bdda00f-d661-4901-bf4c63900011cb0d/human -fertilisation-and-embryo lo gy-authority-access-to-anonymised-data
[https://perma.cc/U2HR-C5B2].
81
About Us, supra note 78.
82
Id.
83
See HUMAN FERTILISATION & EMBRYOLOGY AUTH., ANNUAL REPORT AND ACCOUNTS 2012/13 1, 8-9
(2013), http://www.hfea.gov.uk/docs/HFEA_Annual_Report_and_Accounts_20l 2 - l3.PDF [hereinafter 2013
ANNUAL REPORT]; see Human Fertilisation and Embryology Act, 1990, c. 37, §§ 5-10 (Eng.); Calandrillo &
Deliganis, supra note 77, at 333; About Us, supra note 78.
84
See 2013 ANNUAL REPORT, supra note 83, at 8. The "Human Fertilisation and Embryology Act 2008" is
generally referred to as "the 2008 Act."
85
See Heled, supra note 27, at 284-85.
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regulation of ART, in addition to incorporating the guidelines of various physician
societies, including the " ... British Andrology Society and the British Fertility
Society." 86 The Code of Practice is intended to aid with compliance with the 1990 Act
and contains a number of mandatory requirements, such as those related to counseling,
informed consent and parenthood, that apply to HFEA-licensed activities.87
In 2013, the United Kingdom considered streamlining its healthcare-related
bureaucracy in order to reduce administrative costs incurred by its National Health
Service. 88 One of the options considered was the possibility of transferring the functions
of the HFEA and Human Tissue Authority to the Commission on Quality Control and
the Health Research Authority. 89 At the same time, the HFEA and its decisions have
been criticized on a number of grounds, including those based on policy, the speed of
using certain assisted reproductive technologies in humans, the use of ART, and the
perspectives underlying the agency's decisions.90 In keeping with the general tendency
in the United Kingdom to conduct public consultations when undertaking policy or legal
changes, the UK conducted a public consultation on the continued existence of the
HFEA.9 1 In January 2013, "the Department of Health announced that the HFEA would
Id. at 285; HUMAN FERTILISATION & EMBRYOLOGY AUTH., CODE OF PRACTICE 11 (9th ed. 2019),
https://www.hfea.gov.uk/media/2793/20l9-0l -03-code-of-practice-9th-edition-v2.pdf ("One of the ways we
help licensed centres comply with the Act is by publishing the Code of Practice. This is because we have a
duty under the Act to maintain a document that gives guidance about licensed activities and the people who
carry them out. The Code of Practice contains regulatory principles for licensed centres, and guidance notes
which provides guidance to help clinics deliver safe, effective and legally compliant treatment and research.
Guidance in the Code of Practice also serves as a useful reference for patients, donors, donor-conceived
people, researchers and those working in the fertility sector.") [hereinafter CODE OF PRACTICE].
87
CODE OF PRACTICE, supra note 86, at 11-12 (noting that the Code of Practice contains "mandatory
requirements[,]
.[,] . . . interpretation of mandatory requirements[,] guidance [and o]ther legislation,
professional guidelines and information.").
88
See Press Release, Dept. of Health, Fertility and Tissue Regulators to be Reviewed Following Consultation,
(Jan. 25, 2013) (Eng.),, http:l/mediacentre.dh.gov.uk/2013/01/25/fertility-and-tissue-regulators-to-be
reviewed-following-consultation/ [https://perma.cc/EH3C-2ZM7].
89
For more information on the roles of the Human Tissue Authority, Care Quality Commission, and Health
Research Authority, see id.; DEP'T OF HEALTH, GOVERNMENT RESPONSE TO THE CONSULTATION ON
PROPOSALS TO TRANSFER FuNCTIONS FROM THE HUMAN FERTILISATION AND EMBRYOLOGY AUTHORITY
AND
THE
HUMAN
TISSUE
AUTHORITY
6-8
(2013),
https://assets.publishing.service.gov.uk/govermnent/uploads/system/uploads/ attachment_data/file/212742/C
onsultation_HFEA_and_HTA_govermnent_response.pelf [hereinafter GOVERNMENT RESPONSE].. For public
responses to the public consultation related to the continued existence of the HFEA, see DEP 'T OF HEALTH,
CONSULTATION ON PROPOSALS TO TRANSFER FuNCTIONS FROM THE HUMAN FERTILISATION AND
EMBRYOLOGY AUTHORITY AND THE HUMAN TISSUE AUTHORITY: RESPONSES (2013).
90
See David Adamson, Regulation of Assisted Reproductive Technologies in the United States, 39 FAM. L.Q.
727, 739 (2005); Lyndsey Craven et al., Research into Policy: A Brief History of Mitochondrial Donation, 34
STEM CELLS 265, 265 (2016); Katherine Drabiak, Emerging Governance of Mitochondrial Replacement
Therapy: Assessing Coherence Between Scientific Evidence and Policy Outcomes, 20 DEPAUL J. HEALTH
CARE L. 1, 20 (2018); Gitter, supra note 74, at 1008; Lyria B. Moses, Understanding Legal Responses to
Technological Change of In Vitro Fertilization, 6 MINN. J.L. SCI. & TECH. 505, 603 (2005) (stating
"Restrictions on the freedom of clinicians to determine what is best for each individual patient in the context
of multiple embryo transfer is the most common criticism of HFEA by clinics."); Riley & Merrill, supra note
74, at 53 ("HFEA has frequently been criticized as overly 'pro-choice."); Helene S. Shapo, Frozen Pre
Embryos and the Right to ChangeOne's Mind, 12 DUKE J. COMP. & INT'L L. 75, 99 (2002).
91
HUMAN FERTILISATION & EMBRYOLOGY AUTH., ANNUAL REPORT & ACCOUNTS, CHAIR AND CHIEF
EXECUTIVE'S
FOREWORD
4-5
(2012-2013),
http://www.hfea.gov.uk/docs/HFEA_Annual_Report_and_Accounts_20l 2 - l3.PDF [hereinafter CHAIR AND
CHIEF EXECUTIVE'S FOREWORD];_see GoVERNMENT RESPONSE, supra note 89.). For more on the public
consultation process in the United Kingdom, see UK CABINET OFFICE, CONSULTATION PRINCIPLES 2018
(2018). For more on public consultations generally, see Bojan Bugaric, Openness and Transparency in Public
Administration: Challenges for Public Law, 22 WIS. INT'L L.J. 483, 502-4 (2004); Andrew Edgar,
86
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be retained as an independent regulator. .. follow[ing] a public consultation in which 75
percent of respondents argued that retaining the HFEA as a specialist expert regulator
was in the best interests of patients and the fertility sector." 92
2.

Regulation of Mitochondrial Transfer in the United Kingdom
In order to legalize the use of mitochondrial transfer in the United Kingdom,
the UK's govermnent initiated a number of statutory and regulatory changes. The 2008
Amendment of the Human Fertilisation and Embryology Act "introduce[ed] new
powers which allow for Regulations to be passed by Parliament that will allow
techniques that alter the DNA of an egg or embryo to be used in assisted conception, to
prevent the transmission of serious mitochondrial disease." 93 The 2008 Act addresses,
among other issues, the legal parentage of children conceived as a result of newer forms
of ART, such as mitochondrial transfer and posthumously conceived children. 94
Before approving the use of mitochondrial transfer in the United Kingdom,
however, the HFEA undertook a number of scientific reviews and a five-strand public
consultation.95 After a public consultation on the topic of mitochondrial transfer in
March 2013, the United Kingdom's HFEA "concluded there was 'general support' for
the idea and that there was no evidence that the advanced form of IVF was unsafe." 96
The UK's five-strand public consultation included a number of information gathering
methods, including " ... deliberative public workshops, ... [a] public representative
survey, ... [an] open consultation questionnaire, ... open consultation meetings ... and
patient focus groups."97
The United Kingdom's Department of Health produced draft regulations, and
an amendment to the Human Fertilisation and Embryology Act was approved by the
House of Lords at the end of February 2015. 98 Sally Cheshire, the chairwoman of the
HFEA, said:

Administrative Regulation- Making: Contrasting Parliamentary and Deliberative Legitimacy, 40 MELB. U. L.
REV. 738, 751-52 (2017). For more on public consultations in the United Kingdom related to assisted
reproductive technology, see Mary L. Shanley, Collaboration and Commodification in Assisted Procreation:
Reflections on an Open Market and Anonymous Donation in Human Sperm and Eggs, 36 L. & SOC'Y REV.
257, 274 n.35 (2002); Benjamin B. Williams, Screening for Children: Choice and Chance in the "Wild West "
of Reproductive Medicine, 79 GEO. WASH. L. REV. 1305, 1327 (2011).
92
See CHAIR AND CHIEF EXECUTIVE'S FOREWORD, supra note 91, at 4-5; GOVERNMENT RESPONSE, supra
note 89.
93
HUMAN FERTILISATION &EMBRYOLOGY AUTH., MITOCHONDRIA REPLACEMENT CONSULTATION: ADVICE
TO GOVERNMENT 8 (2013), https://www.hfea.gov.uk/media/2618/mitochondria_replacement_consultation_
_advice_for_govermnent.pdf[hereinafter ADVICE TO GoVERNMENT]; see Joan Mahoney, Genome Mapping
and Designer Babies: A Comparative Perspective, 79 UMKC L. REV. 309, 312 (2010) (discussing the
scientific and social motivations for the 2008 Amendment to the 1990 Act).
94
See CHAIR AND CHIEF EXECUTNE'S FOREWORD, supra note 92, at 8; Maya Sabatello, Posthumously
Conceived Children: An International and Human Rights Perspective, 27 J.L. & HEALTH 29, 36 (2014).
95
ADVICE TO GOVERNMENT, supra note 93, at 7.
96
See James Gallagher, UK Government Backs Three- Parent WF, BBC NEWS (June 27, 2013),
www.bbc.co.uk/news/health-23079276 [https://perma.cc/5KDD-LP3F]; see also CHAIR AND CHIEF
EXECUTNE'SFOREWORD, supra note 9 l_(characterizing support for mitochondrial replacement as "broad").
97
SARAH
BARBER
& PETER
BORDER,
MITOCHONDRIAL
DONATION
13
(2015),
https://researchbriefings.files.parliament.uk/documents/SN06833/SN06833.pdf.
98
See Brittany Shoot, 3- parent WF: Why Isn't it Available in the United States?, THE GUARDIAN (Feb. 27,
2015),
http://www.theguardian.com/sustainable-business/2015/feb/27/3-parent-ivf-us-mitochondria-dna
babies [https://perma.cc/RHM9-96VA]. For more on lawmaking in the UK, see sources cited supra notes 5863.
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Britain is the first country in the world to permit this treatment, and it is a
testament to the scientific expertise and well-respected regulatory regime that
exists across the UK that Parliament has felt able to approve it ... The HFEA
has a long tradition of dealing with medical and scientific breakthroughs,
ensuring that IVF techniques, pioneered in the UK and now practised across
the world, can be used safely and effectively in fertility treatment. 99
While notice-and-comment rulemaking is a hallmark of American
administrative law, the United Kingdom's experience with mitochondrial transfer went
far beyond notice-and-comment mlemaking in terms of the depth and breadth of the
UK's consultation and scientific inquiry into mitochondrial transfer. 100 As noted by the
Parliamentary Office of Science and Technology, "[t]he techniques (maternal spindle
transfer and pronuclear transfer) have been subject to three scientific reviews (2011,
2013 and a further update in 2014), [focused on safety and efficacy,] by a Human
Embryology and Fertilisation Authority expert panel, an ethical review by the Nuffield
Council on Bioethics and a HFEA public consultation." 101 A fourth scientific review
was completed in November 2016. 102 The UK's Chief Medical Officer noted, on the
subject of mitochondrial transfer, "[t]he only clinical tests you can do are either in rats,
mice and monkeys - and those have been done - or in humans and the mothers now
want to do this following those three scientific reviews." 103
As noted earlier, the HFEA public consultation consisted of five strands. 104 The
first strand was composed of deliberative public workshops. 105 The first meetings of the
deliberative public workshops focused on helping members of the public understand the
science underlying mitochondrial donation techniques and mitochondrial disease, which
See Gallagher, supra note 96.
Nina A Mendelson, Rulemaking, Democracy, and Torrents of E-Mail, 79 GEO. WASH. L. REV. 1343, 134344 (2011).
101
See BARBER & BORDER, supra note 97, at I. For the "three scientific reviews" ofmitochondrial transfer
(and the 2014 addendum to the "further update in 2014"), see generally HUMAN FERTILISATION &
EMBRYOLOGY Aurn., ANNEX VIII: SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY OF METHODS TO
AVOID MITOCHONDRIAL
DISEASE THROUGH ASSISTED CONCEPTION: UPDATE (2013), https://www.hfea.gov.uk/media/2612/mito 
annex_viii-science_review_update.pdf; HUMAN FERTILISATION & EMBRYOLOGY Aurn., REVIEW OF THE
SAFETY AND EFFICACY OF POLAR BODY TRANSFER TO AVOID MITOCHONDRIAL DISEASE ADDENDUM TO
'THIRD SCIENTIFIC REVIEW OF IBE SAFETY AND EFFICACY OF METHODS TO AVOID MITOCHONDRIAL
DISEASE
THROUGH
ASSISTED
CONCEPTION:
2014
UPDATE'
(2014),
HUMAN
https://www.hfea.gov.uk/media/2610/2014-10-07_-_polar_body_transfer_review_-_final.pdf;
FERTILISATION &EMBRYOLOGY AUTH., SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY OF MEIBODS TO
AVOID
MITOCHONDRIAL
DISEASE
THROUGH
ASSISTED
CONCEPTION
(2011),
https://www.hfea.gov.uk/media/2613/scientific-review-of-the-safety-and-efficacy-of-methods-to-avoid
mitochondrial-disease-through-assisted-conception.pdf; HUMAN FERTILISATION & EMBRYOLOGY Aurn.,
THIRD SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY OF MEIBODS TO AVOID MITOCHONDRIAL DISEASE
THROUGH
ASSISTED
CONCEPTION:
2014
UPDATE,
(2014),
https://www.hfea.gov.uk/media/2614/third_mitochondrial_replacement_scientific_review .pdf.
102
See HUMAN FERTILISATION & EMBRYOLOGY Aurn., SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY
OF METHODS TO AVOID MITOCHONDRIAL DISEASE THROUGH ASSISTED CONCEPTION: 2016 UPDATE 4-5
(2016), https://www.hfea.gov.uk/media/261 l /fourth_scientific_review_mitochondria_2016.pdf [hereinafter
2016 UPDATE].
103
See Steve Connor, Chief MedicalOfficer Urges Lords to Legalise 'Three- Parent' IVF, THE INDEPENDENT
(Feb. 24, 2015), http://www.independent.co.uk/news/science/chief-medical-officer-urges-lords-to-legalise
three-parent-ivf-10065833.html [https://perma.cc/Q2CM-736D].
104
See ADVICE TO GOVERNMENT, supra note 93.
105
See id. at 10-11.
99

100

148

AMERICAN JOURNAL OF LAW & MEDICINE

VOL. 45 NO. 2-3 20 19

could numnuze sensationalism of press coverage. 106 The "second events [of the
deliberative public workshops] focused on the social and ethical issues relating to the
techniques." 107 The second strand of the UK's public consultation included nearly 1,000
face-to-face interviews with members of the public on a number of topics related to
mitochondrial disease, treatment of genetic disease and ART. 108 Third, open
consultation meetings "involved a combination of small group discussions around
particular issues, whole group debates, and discussion between and across the panel and
the floor." 109 Fourth, the "open consultation questionnaire" permitted interested
members of the public to consider information posted on a public consultation website
before submitting responses to seven specific questions through the mail or online. 110
Fifth, there was a patient focus group, composed of individuals who had been directly
or indirectly affected by mitochondrial disease. rn The aforementioned five-strand
public consultation contained a number of methods that parallel the American
administrative law consultation process or that could be adapted to a public consultation
in the United States on the topic of mitochondrial transfer, and ultimately, other
technologies involving genetic modification.
3.

The Role of Non-Govermnental Bodies
Non-govermnental bodies such as the aforementioned National Academies of
Sciences in the United States and the Nuffield Council on Bioethics in the United
Kingdom aid national govermnents in decision-making related to assisted reproductive
technology, especially mitochondrial transfer. 112 For example, in one of the Nuffield
Council's reports, NOVEL TECHNIQUES FOR THE PREVENTION OF MITOCHONDRIAL DNA
DISORDERS: AN ETHICAL REVIEW, the Nuffield Council on Bioethics "[a]s an
independent body . . . sought to identify the novel ethical issues raised [by mitochondrial
replacement therapies], while also looking deeper into the issues which have already
featured in the public debate about these techniques." 113 This Report was cited to in
numerous influential documents issued by the HFEA and UK Parliamentary offices in
relation to the UK Parliament's ultimate changing of the regulations to permit the use of
mitochondrial transfer in the United Kingdom. 114
UNITED STATES

B.
106

Id.

107
Id.

at 1 1, 22.
at 11.

Id.
Id.
110
See ADVICE TO GOVERNMENT, supra note 93, at 11.
111
Id.
112
See infra note 160 and accompanying text (discussing the National Academy of Science's report completed
at the request of the FDA); see also About, NUFFIELD COUNCIL ON BIOEIBICS,
10s
109

http://nuffieldbioethics.org/about [https://perma.cc/494C-8ZHS] ("The Nuffield Council on Bioethics is an
independent body that examines and reports on ethical issues in biology and medicine. It was established by
the Trustees of the Nuffield Foundation in 1991, and since 1994 it has been funded jointly by the Foundation,
Wellcome and the Medical Research Council. The Council has achieved an international reputation for
advising policy makers and stimulating debate in bioethics.")
1 13
NUFFIELD COUNCIL ON BIOEIBICS, NOVEL TECHNIQUES FOR IBE PREVENTION OF MITOCHONDRIAL DNA
DISORDERS:
AN
EIBICAL
REVIEW
viii
(2012),
http://nuffieldbioethics.org/wp
content/uploads/2014/06/Novel_techniques_for_the_prevention_of_mitochondrial_DNA_disorders_compre
ssed.pdf.
114
See ADVICE TO GOVERNMENT, supra note 93 at 10; 2016 UPDATE, supra note 102 at 32; BARBER &
BORDER, supra note 97, at 5 (stating "information . . . to Members of Parliament in support of their
parliamentary duties").
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While the United Kingdom was the site of the birth of the first child
conceived using ART, many innovations in ART have developed in the United States.
In 2014, there was significant media coverage of the work of Dr. Shoukhrat Mitalipov
at the Oregon Health & Science University in the realm of maternal spindle transfer, one
of the two forms of mitochondrial transfer. 1 15 More recently, Dr. John Zhang, a New
York-based physician traveled to Mexico to prevent the transmission of Leigh
Syndrome, a mitochondrial disease, using mitochondrial transfer. 116 Before that in the
1990s and early 2000s, a number of American physicians were providing cytoplasmic
transfer, which was similar to mitochondrial transfer, in order to improve women's
fertility. 117 Yet, in all of these aforementioned instances, innovation was stymied in
several ways. The FDA sent letters to physicians providing cytoplasmic transfer, stating
that in order to continue providing these techniques to their patients, they had to obtain
approval through the FDA's investigational new drug approval process.118 In the case of
more recent innovations in mitochondrial transfer, the FDA responded with continued
declarations of its jurisdiction over the technique through letters to physicians and
general declarations. 119 Subsequently, Congressional budget riders have prohibited the
agency from considering licenses for ART techniques involving genetic modification. 120
This part explores both the federal and state regulation of ART (including advanced
assisted reproductive technologies) in the United States.
1.
The American Regulatory Framework Governing Assisted Reproductive
Technology Use and Innovation
Historically, there has been little state or federal regulation of ART, which
allowed the industry to develop with little regulatory oversight. 12 1 The prevailing view
is that ART in the United States is minimally regulated or unregulated; however, forms
of ART involving genetic modifications are highly regulated in the United States, albeit
through formally non-binding documents issued by the federal government that
nonetheless have practically binding effects. 122 For those forms of ART that are more
Sabrina Tavernies, His Fertility Advance Draws Ire, N.Y. TIMES (Mar. 17, 2014).
See John Zhang et al., Live Birth Derived fromOocyte Spindle Transfer to Prevent Mitochondrial Disease,
34 REPROD. BIOMEDICINE ONLINE 361, 361-68 (2017) (discussing the use of mitochondrial donation treatment
in a patient with Leigh Syndrome by Dr. John Zhang and other colleagues at the New Hope Fertility Center,
which has offices in New York and Mexico).
1 17
See Subterranean Regulation, supra note 5, at 1250, 1260; see also Charlotte Pritchard, The Girl with Three
Biological Parents, BBC NEWS: MAG (Sept. 1, 2014), https://www.bbc.com/news/magazine-28986843
[https://perma.cc/HK49-M74V].
118
Subterranean Regulation supra note 5, at 258. For the full letter, see id. at 1289-91.
119
See Letter from Mary A Malarkey, Dir., Office of Compliance & Biologics Quality, Ctr. for Biologics
Evaluation & Research, U.S. Food & Drug Admin., to John Zhang, CEO, Darwin Life, Inc. & New Hope
Fertility Center (Aug. 4, 2017), https://www.fda.gov/media/106739/download [hereinafter FDA Letter]; see
also Advisory on Legal Restrictions on the Use of Mitochondrial Replacement Techniques to Introduce Donor
Mitochondria into Reproductive Cells Intended for Transfer into a Human Recipient, Cellular & Gene Therapy
Products,
U.S.
FOOD
&
DRUG
ADMIN.
(Mar.
16,
2018),
https://www.fda.gov/biolo gicsbloodvaccines/cellulargenetherapyproducts/ucm570185.htm
[https://perma.cc/RW6M-S9EN] ("The clinical use of [mitochondrial replacement therapy] in the United
States falls within FDA's regulatory authority.") [hereinafter MRT Legal Restrictions].
120
See, e.g., FDA Letter, supra note 119; MRT Legal Restrictions, supra note 119.
121
Lori B. Andrews & Nanette Elster, Regulating Reproductive Technologies, 21 J. LEGAL MED. 35, 35-44
(2000) (providing historical overview of ART).
122
See Subterranean Regulation, supra note 5, at 1241 n.l , 1259, 1270; see also Heled, supra note 27, at 247
(noting the "dearth of state law and a total lack of federal law regulating the genetic aspects of [donated
reproductive tissue]"); Rosato, supra note 36, at 57, 63 ("Assisted reproductive technology (' ART') has been
in existence for twenty-five years with very little oversight or regulation." (citations omitted)).
115
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"traditional," and similar to the ART of the 1970s, such as IVF (without genetic
modifications) and artificial insemination, the traditional characterization of the
regulation of ART remains accurate as states and the federal govermnent provide little
regulation of ART that does not involve genetic modification. 123
As noted in part II.B supra, the Fertility Clinic Success Rate and
Certification Act is the only federal statute that regulates ART. 124 In spite of the
existence of only one statute that applies to ART regulation, 125 the FDA has used its
power to stymie the use of forms of ART that involves genetic modifications in the
United States.
First, the agency used notice-and-comment rulemaking to promulgate its
Human Cellular and Tissue-Based Products regulation, which became a final rule in
2001. 126 This final rule created a framework in which "more than minimally
manipulated" tissue is subject to the agency's investigational new drug requirements. 127
Despite comments received during the notice-and-comment rulemaking process stating
that the term "minimal manipulation" was vague and should be eliminated, the agency
retained the term and its associated framework. 128 Ultimately, that framework has been
applied to innovations in ART, which are characterized by the FDA as involving "more
than minimal manipulation," thus requiring the use of an investigational new drug
application under federal law, instead of being categorized as simply the practice of
medicine. 129
Subsequent to the effective date of the Human Cellular and Tissue-Based
Products rule, the agency issued a number of documents, based on that regulation,
stating that the agency has jurisdiction over forms of ART involving genetic
modification, without clearly explaining what statutes accorded it such jurisdiction. 130
See Subterranean Regulation, supra note 5,at 1270-71 n.136.
See 42 U.S.C. § 263a-l (2012).
125
See id.
126
See Human Cells, Tissues,and Cellular and Tissue-Based Products; Establishment Registration and Listing,
66 Fed. Reg. 5447,5452 (Jan. 19, 2001); Tissue and Tissue Product Questions and Answers, U.S. FOOD &
123

124

DRUG

ADMIN.,

http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/QuestionsaboutTissues/ucm l 0 l 559.htm
[https://perma.cc/88NS-G2XS].
127
Human Cells,Tissues,and Cellular and Tissue-Based Products; Establishment Registration and Listing,66
Fed. Reg. at 5452.
128
Id. at 5457 ("Eight comments asserted that 'minimal manipulation' is vague and open to subjective
interpretation, and should be eliminated. Two comments asserted that it is difficult to draw a meaningful
distinction between tissues that are minimally manipulated and those that are more than minimally
manipulated. One of these comments suggested that instead of the minimal manipulation criterion, FDA
should propose that tissue products labeled or promoted for tissue replacement,reconstruction,or restoration
of function be regulated as tissue. Another comment requested the development of guidance and noted that,
in light of future technological advances, a broader definition of minimal manipulation may be more
appropriate."). Overall, the FDA received "28 comments on the proposed rule as it was published in 1998
[and] over 400 comments on the donor-suitability proposed rule; many of these raised issues related to subparts
A and B of part 1271." Id. at 5450. Comments related to the term "minimal manipulation" were addressed
with the other comments on Comments on Subpart A: Proposed Sectionl 271.10 and Section 1271.15 (Final
Section 1271.10 and Section 1271.20). Id. at 5450,5453,5457.
129
See Halted Innovation, supra note 7,at l lOO.
130
See id. § 553(b)(3) ("Except when notice or hearing is required by statute,this subsection [requiring notice
of proposed mlemaking] does not apply . . . to interpretive mies, general statements of policy, or mies of
agency organization, procedure, or practice"); see also Advisory on Legal Restrictions on the Use of

Mitochondrial Replacement Techniques to Introduce Donor Mitochondria into Reproductive Cells Intended
for Transfer into a Human Recipient, Cellular & Gene Therapy Products, U.S. FOOD & DRUG ADMIN. (Mar.

16, 2018), https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/ucm570185.htrn
[https://perma.cc/9STE-Q4LF].

AMERICAN JOURNAL OF LAW & MEDICINE

15 1

These documents, issued by the FDA, were part of a larger trend in which many agency
decisions escape notice-and-comment rulemaking, thereby eliminating the opportunity
for the public to provide comments on proposed federal regulations and agency action. 13 1
As numerous scholars have noted, many agencies rely upon informal methods
of guidance to regulate, instead of issuing mles. 132 First, informal guidance methods are
not subject to public comment. 133 Second, their informal nature makes it much harder
for the public to rely on those mechanisms or to even know that those mechanisms exist
although, at the same time, various court opinions have noted that guidance documents
have binding effect even though they are not subject to the notice-and-comment process
and contain disclaimers stating that they are not binding. 134 Although assisted
reproductive technology providers have not commenced litigation related to the FD A's
pronouncements on the effects "minimal manipulation" framework as detailed in non
legislative documents to assisted reproductive technology, it is worth noting that a
significant amount of administrative law literature and court decisions have focused on
ascertaining when agency pronouncements should be categorized as legislative rules,
which are subject to notice-and-comment mlemaking, as opposed to as interpretive or
non-legislative rules which are not. 135 While some regulated entities appreciate informal
agency pronouncements because those announcements permit them to perhaps cease
actions that might result in domestic enforcement actions, 136 others are troubled by these
13 1
See WILLIAM N. ESKRIDGE JR., STATUlES, REGULATION, AND lNlERPRETATION: LEGISLATION AND
ADMINISTRATION IN IBE REPUBLIC OF STATUTES 713-16, 838 (2014).
132 Id.
at 838; Richard A. Epstein; The Role of Guidances in Modern Administrative Procedure: The Case for
De Novo Review, 8 J. OF LEG. ANALYSIS 47, 47-48, 58-83 (2016) (discussing the evolution of the current use
of guidance documents by administrative agencies); David L. Franklin, Legislative Rules, Nonlegislative
Rules, and the Perils of the Short Cut, 120 YALE L.J. 276, 278, 286-89 (2010); Matk Seidenfeld, Substituting
Substantive for Procedural Review of Guidance Documents, 90 TEX. L. REV. 331, 332-8 and 340-4 (2011).
133
Epstein, supra note 132, at 47.
134
Halted Innovation, supra note 7, at 1098.
135
See e.g. Matk Seidenfeld, Substituting Substantive for Procedural Review, 90 TEX. L. REV. 331, 332 and
350-2; Id. at 360-1 ("For interpretive mies, the message from the courts is that the weaker the link between
the interpretation and the text of the statute or regulation being interpreted, the less likely a court is to allow
the agency to announce the interpretation by guidance document."); Perez v. Mortgage Bankers Ass'n, 135 S.
Ct. 1199, 1208 (2015); Appalachian Power Co. v. EPA, 208 F.3d 1015, 1021 and 1024-5 (2000); General
Electric Co. v. EPA, 290 F.3d 377, 380-85 (2002); Nat'! Min. Ass'n v. Sec'y of Labor, 589 F.3d 1368, 137173 (2009). For more on the disparate tests used to ascertain whether a document that the agency has classified
as a non-legislative rule actually required notice-and-comment because it actually should have been issued as
a legislative rule, see e.g. Kristin Hickman, Unpacking the Force of Law, 66 VAND. L. REV. 465, 480-84
(2013); Id. at 503 at n. 205, 513; David L. Franklin, Legislative Rules, Nonlegislative Rules, and the Perils of
the Short Cut, 120 YALE L. J. 276, 284 (2010)(discussing the concern that agencies "strategically" use non
legislative documents to avoid the notice-and-comment rulemaking process and the various tests that courts
use to ascertain whether a "document promulgated without notice and comment is really a legislative rule and
is therefore procedurally invalid," including the "legal effect test" and the "substantial impact test."). See also
Kelley v. E.P.A., 15 F.3d 1100, 1108 (D.C. Cir. 1994); Appalachian Power Co. v. EPA ("We must still look
to whether the interpretation itself carries the force and effect of law, ..or rather whether it spells out a duty
fairly encompassed within the regulation that the interpretation purports to construe" citing to Paralyzed
Veterans v. D.C. Arena L.P., 117 F. 3d 579, 588 (D.C. Cir. 1997). See also infra note 131.
136
Subterranean Regulation, supra note 5, at 1259-60 (describing the reactions of physician-researchers after
receiving letters from the FDA which was to cease their research or medical practice or move it abroad).
Beyond the reactions of physicians and researchers after receiving letters from the FDA, examining the
agency's letters through the lens of the tests that courts have used to ascertain whether guidance documents
should be treated as legislative mies, many aspects of those agency rules lend themselves to arguments that
the agency documents explaining the application of the "minimal manipulation rule" should be treated as
legislative mies as opposed to non-legislative mies. For example, while the FDA's letters to researchers in
2001 did not specifically state that their specific work was subject to the FDA's regulation, the letter used
mandatory language: "The use of such genetically manipulated cells (and/or their derivatives) in humans
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informal agency pronouncements because they create an uncertainty, having provided
an agency view in a non-binding document. 137 The goal of notice-and-comment
regulations is said "to discipline agency decision making and promote public-regarding
(i.e., nonarbitrary) action by agencies," although many types of decisions, including
nonenforcement decisions and decisions supported by guidance documents, are not
subject to public comment. 138
Congressional budget riders can also stymie innovation. Congress has enacted
(and renewed annually) budget riders that restrict the funding of certain embryonic stem
cell research projects since 1996, and the FDA's review of applications involving
genetic modification since 2015. 139 These riders have been enacted without a defined
consultation with the public on these matters and in at least one case, without any

constitutes a clinical investigation and requires submission of an Investigational New Drug application (IND)
to FDA." Letter from U.S. Food & Drug Admin.,to Sponsors/Researchers - Human Cells Used in Therapy
Involving the Transfer of Genetic Material by Means Other Than the Union of Gamete Nuclei (May 6,2009);
see e.g.Ronald M. Levin,Rulemaking and the Guidance Exemption, 70 ADMIN. L. REV. 263, 294-98 (2018)
(discussing courts' analysis of mandatory language in litigation related to whether agency documents are in
fact legislative mies despite being labeled otherwise). The reactions of physicians and researchers to the
FDA's letters which purport to "advise" addressees of the agency's jurisdiction and requirements indicates
that those letters and the agency's interpretations have "the force and effect of law." See Am. Mining Cong.
v. Mine Safety & Health Admin., 995 F.2d 1106, 1108-09 (D.C. Cir. 1993). For those who received the
agency's letters in 2001, they stopped providing the technique in the United States. Similarly,in 2017, Dr.
John Zhang, who provided the technique in Mexico, to avoid the U.S. regulatory system, later submitted an
investigational new drug application so as to offer the technique in the United States in accordance with the
FDA's statements of what was required by the statute (as explained through the Human Cellular and Tissue
based Products rule and the agency's subsequent pronouncements in non-legislative documents). See supra
note 116 and accompanying text. In sum,the effect of these agency statements regarding its jurisdiction over
forms of assisted reproductive technology involving genetic modification is that researchers adhere to the
FDA's framework, as explained in guidance documents and either cease offering (and researching) the
technique altogether or cease offering the technique in the United States specifically in order to avoid the
FDA's jurisdiction. Thus, these agency interpretations carry the "force and effect of law." See Appalachian
Power Co. v. EPA,208 F.3d 1015,1024 (2000); but see Perez v. Mortgage Bankers Assoc.,135 S. Ct. 1199,
1207-11 (2015) (explaining that agencies do not have to use notice-and-comment mlemaking when
"significantly alter[ing] a prior, definitive interpretation of a regulation'' as was previously required by
Paralyzed Veterans);). But see Gwendolyn Mc Kee, Judicial Review of Agency Guidance Document:
Rethinking the Finality Doctrine, 60 ADMIN. L. REV. 371, 380, 390-97 7(discussing the FDA's statutory
disclaimer related to the binding nature of guidance documents and litigation related to guidance documents
in the context of the FDA). For post-Perez discussion of various tests still used to interpret whether an agency
decision is a legislative or non-legislative rule,see generally Ronald M. Levin,Rulemaking and the Guidance
Exemption, 70 ADMIN. L. REV. 263 (2018); Cass R. Sunstein, "Practically Binding ": General Policy
Statements and Notice- and- Comment Rulemaking, 68 ADMIN. L. REV. 491,505-088 (2016).
137
See Subterranean Regulation, supra note 5.
138
See Deacon,supra note 41,at 1591.
139
See George Q. Daley,Missed Opportunities in Embryonic Stem- Cell Research, Perspective, 351 N. ENG.
J. MED. 627, 628 (2004) ("Proposed in 1996 by Representative Jay Dickey (R-Ark.) as a rider on the
appropriations bill for the Department of Health and Human Services and renewed every year since, the
Dickey[ -Wicker] Amendment prohibits federal engagement in a field of research pertaining to the nature of
the human embryo,its disorders of development,and the derivation of new human embryonic stem-cell lines.
Although most embryos created in vitro during fertility procedures are deemed unsuitable for pregnancy and
are discarded, federal funds may not be used to ascertain what went wrong."); FDA Letter, supra note 119
("Since December 2015, the United States Food and Drug Administration (FDA) has been prohibited by
Congress in provisions in annual federal Appropriations Acts from using funds to accept IND submissions for
clinical investigations that involve 'a human embryo . . . intentionally created or modified to include a heritable
genetic modification."); see also The Consolidated Appropriations Act,2017,Pub. L. No. 115-31,131 Stat.
173 (2017). For more on the aforementioned Consolidated Appropriations Act provision, see generally I.
Glenn Cohen & Eli Y. Adashi, The FDA is Prohibited From Going Germline, 353 SCIENCE 545 (2016).
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discussion of the rider itself at all. 14° For example, Professor June Carbone noted in
2010, "[g]iven the federal ban on funding embryo research, any preapproval process is
likely to delay if not permanently stall the development of new techniques." 141 Even
though some embryonic stem cell research is now federally funded, it is subject to a
number of limitations, including limits on available stem cell lines for research and
federal appropriations restrictions like the Dickey-Wicker Amendment, which aims to
prevent research on embryos that can result in their destmction. 142
Thus, Congressional action suffers from a lack of discourse on the ethical and
social issues surrounding stem cell research and forms of ART. 143 In the case of
mitochondrial transfer, although this article focuses on the varying approaches of the
United States and United Kingdom regarding mitochondrial transfer, this form of ART
has been offered to patients in other countries, including Mexico. 144 The fact that a New
York based physician traveled to Mexico to provide mitochondrial transfer to a couple
was the subject of media attention not only after the successful birth of a child, but also
in 2017 when the FDA denied the application of the physician for an investigational new
drug application, citing a federal budget rider that prevented them from expending funds
related to applications for investigational new drug applications involving genetic
modification. 145
140
For more on the "scant" legislative history of the Dickey-Wicker Amendment and the surrounding
discussion, see Kerry L. Macintosh, Psychological Essentialism and Opposition to Human Embryonic Stem
Cell Research, 18 J. TECH. L. & POL'Y 229, 252-57 (2013); see also Eli Y. Adashi & I. Glenn Cohen,
Mitochondrial Replacement Therapy: Unmade in the USA, 317 JAMA 555, 574-75 ("The congressional
record is mum on the identity of the sponsor or sponsors of the ban ['which comprises Section 749 of the
Consolidated Appropriation Act of 2016 '], and the precise motives for crafting it remain equally uncertain.
The ban's enactment was all but guaranteed by the complete absence of discussion before its passage or at any
time thereafter, and by its inclusion in a must-pass omnibus appropriation bill."); Kiyan Bigloo, Aggregation
of Powers: Stem Cell Research and the Scope of Presidential Power Examined Through the Lens of Executive
Order Jurisprudence, 18 PSYCHOL. PuB. POL'Y & L. 519, 522-26 (2012); Advisory on Legal Restrictions on
the Use of Mitochondrial Replacement Techniques to Introduce Donor Mitochondria into Reproductive Cells
Intended for Transfer into a Human Recipient, U.S. FOOD & DRUG ADMIN. (Mar. 16, 2018),
https://www.fda.gov/biolo gicsbloodvaccines/cellulargenetherapyproducts/ucm570185.htm
[https://perma.cc/9STE-Q4LF] ("Since December 2015, Congress has included provisions in annual federal
appropriations laws that prohibit FDA from accepting applications for clinical research using MRT. Therefore,
clinical research using MRT in humans cannot legally proceed in the United States. FDA maintains the
authority to investigate and take enforcement action in the event that it becomes aware of noncompliance with
the laws and regulations administered by FDA").
141
June Carbone, Negating the Genetic Tie: Does the Law Encourage Unnecessary Risks?, 79 UMKC L. REV.
333, 354 (2010).
142
See George Annas, Resurrection of a Stem- Cell Funding Barrier - Dickey-Wicker in Court, 363 N. ENG.
J. MED. 1687, 1687-8 (2010) ("The amendment, known as the Dickey-Wicker amendment, provides that no
federal funds can be expended by the National Institutes of Health (NIH) for ' ( l ) the creation of a human
embryo or embryos for research purposes; or (2) research in which a human embryo or embryos are destroyed,
discarded, or knowingly subjected to risks of injury or death.' It has been added to NIH appropriations bills
every subsequent year, just as the Hyde Amendment restricting abortion fnnding is added."); Stem Cell
Information Home Page, 2016, NAT'L INST. OF HEALTH, https://stemcells.nih.gov/research/newcell_qa.htm
[https://perma.cc/5YUZ-DR5W] ("No federal funds may be used, either by an awardee or a sub-recipient, to
support research using derivatives of human embryonic stem cell lines (hESCs) that are not listed on the NIH
Human Embryonic Stem Cell Registry, with the exception described below."); see also FDA Letter, supra
note 119.
143
See Eli Y. Adashi & I. Glenn Cohen, Preventing Mitochondrial Diseases: Embryo- Sparing Donor
Independent Options, Opinion, 24 TRENDS IN MOLECULAR MED. 449, 450 at Box 2 (2018) (citing to the
"theological, ethical, and safety concerns surrounding mitochondrial transfer").
144
See Michelle Roberts, First 'Three Person Baby'Baby' Born Using New Method, BBC NEWS (Sept. 27,
2016), https://www.bbc.com/news/health-37485263 [https://perma.cc/R5Q2-QCZ4].
145
See FDA Letter, supra note 119.
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While much has been written about the risk of agencies being captured by the
industries that they regulate, the example of ART regulation in the United States raises
an additional variation on agency capture. 146 In the realm of traditional ART and
advanced assisted reproductive technologies, the problem is not capture by the industry
(with the industry being the fertility industry or perhaps providers of ART), but perhaps
a type of undue political influence by the executive or groups motivated by specific,
conservative political or social views. For example, issues that tends to surface in
connection with the use of ART, especially innovative ART, are ethical debates related
to the morality of destroying embryos and fetuses and political debates related to the
"personhood" movement, which often surfaces decisions related to the regulation of
techniques that could destroy embryos or fetuses. 147
The FDA has acknowledged the existence of social and ethical issues in the
realm of ART; however, the agency does not create fora for the discussion of those
issues. For example, at a 2014 FDA Advisory Committee meeting at the 2014 FDA
Cellular, Tissue, and Gene Therapies Advisory Committee meeting, on the topic of
mitochondrial transfer, an FDA employee stated that
[t]he FDA recognizes [that there are] moral, ethical, and
social policy issues related to genetic modification of eggs and embryos,
and that these issues have the potential to affect regulatory decisions. However,
these issues are outside of the scope of this advisory committee meeting. 148
In spite of the acknowledgment that ethical and social policy issues could "affect
regulatory decisions[,]" there was no further identification of what exactly those "moral,
ethical, and social policy issues" were or a subsequent meeting to discuss these issues
generally or how they might "affect regulatory decisions" specifically. 149 By not
discussing the moral, ethical, and social policy issues that can impact regulatory
decisions, the administrative state allows conservative moral, ethical, and social policy
issues to be the default view of the administrative state: conservative perspectives would
desire the halting of innovation in ART and the current system supports that goal by not
assessing whether other views might be relevant (or prevalent). At least in the realm of
ART, and also a number of associated technologies including gene editing and
technologies that result in germline modifications, social groups or at the very least,

146
Deacon, supra note 41, at 160 l ; Lyria B. Moses, Understanding Legal Responses to Technological Change:
The Example of in Vitro Fertilization, 6 MINN. J.L. SCI. & TECH. 505, 581-82 (2005).
147
See June Carbone & Naomi Calm, Embryo Fundamentalism, 18 WM. &MARY BILL RTS. J. 1015, 1017-18
(2010); I. Glenn Cohen & Eli Y. Adashi, Embryo Disposition Disputes: Controversies and Case Law, 46
HASTINGS C1R. REP. 13, 15-16 (2016); Janet L. Dolgin, Embryonic Discourse: Abortion, Stem Cells, and
Cloning, 31 FLA. ST. U. L. REV. 101, 104-06, 146 (2003); Michele Goodwin, Fetal Protection Laws: Moral
Panic and the New Constitutional Battlefront, 102 CAL. L. REV. 781, 785 (2014); King, supra note 27, at 323
("Political debate over embryo creation and destruction often causes people to retreat to their firmly entrenched
positions on abortion, which contributes significantly to the regulatory stalemate with respect to ART in the
United States." (citation omitted)); Maya Manian, Lessons from Personhood's Defeat: Abortion Restrictions
and Side Effects on Women's Health, 74 OHIO ST. L.J. 75, 77 (2013); Mary Ziegler, Beyond Balancing:
Rethinking the Law of Embryo Disposition, 68 AM. U. L. REV. 515, 523-24 (2018).
148
U.S. FOOD & DRUG ADMIN., TRANSCRIPT OF CENTER FOR BIOLOGICS EVALUATION AND RESEARCH,
CELLULAR, TISSUE, AND GENE THERAPIES ADVISORY COMMITTEE MEETING #59 13 (2014) [hereinafter
MEETING #59 TRANSCRIPT].
149
Id.; see Subterranean Regulation, supra note 5, at 1271-74.
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conservative social views, have managed to capture the regulatory process. 150 If the
federal government is going to continue to make decisions that likely involve some sort
of ethical viewpoint, it is important to note that different polities have different ethical
views. Thus, to the extent that administrative agencies are seen as more transparent than
Congress, one option is to proceed in a manner that allows for that transparency through
notice-and-comment, instead of allowing agency staff to make regulatory decisions
related to assisted reproductive technology without public input.
In addition to federal regulation, there are numerous state statutes that address
ART. 15 1 Some states have mandated insurance coverage of fertility treatments or the
offer of insurance coverage of fertility treatments. 152 Some states have clarified the
extent to which insurance coverage does or does not mandate coverage of fertility
treatments. 153 States have also enacted statutes requiring that fertility clinics inform
patients of the clinics' success rates related to the success of fertility treatments. 154 Just
as states can influence other states, they can also impact the federal government. 155 For
example, many scholars have noted that the Patient Protection and Affordable Care Act
was based on the state of Massachusetts' insurance scheme. 156 Similarly, in the realm of
ART, the federal government now provides insurance coverage for infertility treatments
(including ART) for certain members of the military with service-related disabilities,
although ART remains otherwise uncovered at the federal level. 157
150
Wolf et al., supra note 8, at 73 ("The FDA has also recognized ethical and social policy issues related to
genetic modification of eggs and embryos that will likely affect regulatory decisions."); NIH Statement on
NIH Funding on Research Using Gene- Editing Technologies in Human Embryos, NAT'L INST. OF HEALTH
(Apr. 28, 2015), http://www.nih.gov/about-nih/who-we-are/nih-director/statements/statement-nih-funding
research-using-gene-editing-technologies-human-embryos [https://perma.cc/4WK9-L246] ("However, NIH
will not fund any use of gene-editing technologies in human embryos. The concept of altering the human
germline in embryos for clinical purposes has been debated over many years from many different perspectives,
and has been viewed almost universally as a line that should not be crossed.").
151
See Sonia M. Suter, The "Repugnance'" Lens of Gonzales v. Carhart andOther Theories of Reproductive
Rights: Evaluating Advanced Reproductive Technologies, 76 GEO. WASH. L. REV. 1514, 1516 (2008)
(discussing the role of states in regulating assisted reproductive technology).
152
See State Laws Related to Insurance Coverage for Infertility Treatment, NAT'L CONFERENCE STATE
LEGISLATURES (Apr. 27, 2018), http://www.ncsl.org/research/health/insurance-coverage-for-infertility
laws.aspx# l [https://perma.cc/Z9TX-XU9U] (providing "state laws that require insurers to either cover or
offer coverage for infertility diagnosis and treatment").
153
LA. REV. STAT. § 22:1036 (2009) (describing "[p]rohibited exclusion of coverage of correctable medical
conditions on basis of infertility"); MINN. STAT. § 256B.0625(13)(a) (2018) (stating "[m]edical assistance
covers drugs, except for fertility drugs when specifically used to enhance fertility").
154
See Calandrillo & Deliganis, supra note 76, at 330 (citing VA. CODE § 54.1-2971.1).
155
Miriam Seifter, States as Interest Groups in the Administrative Process, 100 VA. L. REV. 953, 993-94
(2014) ("Phrased another way, federal agencies can work toward fulfilling their expertise-oriented role by
harnessing the information production machine of the federal system--not from abstract arguments regarding
principles of federalism, which may well be beyond the administrative ken, but from the specific, diverse
experiences and information generated by individual states." (citations omitted)).
156
See Gillian E. Metzger, Federalism UnderObama, 53 WM. & MARY L. REV. 567, 602 (2011); Stephen M.
Weiner, Payment Reform After PPACA: Is Massachusetts Leading the Way Again?, 11 YALE J. HEALTH POL'Y
L. & ETHICS 33, 33, 33 n.3 (2011).
157
See DEP'T. VETERANS AFFS., VETERANS HEALTH AFFAIRS DIRECTIVE 1332: INFERTILITY EVALUATION
AND TREATMENT 1-2 (2017), https://www.va.gov/vhapublications/ViewPublication.asp?pub_ID =543 l
[https://perma.cc/FDM9-V5G9] ("establish[ing] policies and procedures for providing infertility evaluation
and treatment to Veterans enrolled in the Department of Veterans Affairs (VA) healthcare system."); see
generally Katie Falloon & Philip M. Rosoff, Who Pays? Mandated Insurance Coverage for Assisted
Reproductive Technology, 16 AM. MED. Assoc. J. OF ETHICS 63, 63 (2014) ("Currently, only about a third of
states have mandated insurance coverage of infertility treatment, but the vast majority of health insurance
plans in other states do not offer coverage; hence, most people pay out of pocket. Furthermore, Medicaid does
not pay for ART anywhere in the US" (citations omitted)); Assisted Reproductive Services, TRICARE (Oct.
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In addition to professional societies in the United States, just as in the United
Kingdom, non-governmental bodies in the United States provide useful advice to
governmental and professional bodies. 158 While innovation in ART has been delayed, at
least as it relates to ART involving genetic modifications at the federal level, there is
still discussion of the techniques by scientists, scholars, the media, and ethicists, but that
discussion does not include those in federal government who would be making decisions
related to the clinical use of ART. In the United States, the closest that the public has
had to a centralized public discourse in health care on new techniques involving genetic
modification is a National Academy of Sciences Report. 159 At the FDA's request, the
National Academy of Sciences convened a committee that wrote a report on the "ethical,
social, and policy issues" implicated by the use of mitochondrial transfer. 160 The
National Academy of Science's Institute of Medicine's 2016 report recommended the
use of mitochondrial transfer under specific conditions. 16 1 Nonetheless, a public
consultation on ART involving genetic modification still has not occurred and advanced
assisted reproductive technology innovation continues to be hindered by the American
administrative state.
IMPLICATIONS OF THE UNITED STATES' DEMOCRATIC DEFICIT
There are at least three broader implications of the American democratic deficit
in ART innovation. First, the regulation of advanced assisted reproductive technologies
by an administrative agency without public input undermines a number of administrative
law values such as transparency, legitimacy, and accountability. 162 Second, the lack of
transparency and public involvement has permitted political concerns to affect scientific
decision-making as agency employees are able to obfuscate the impact of political and
social concerns on regulatory decision-making, especially when science is the subject
of the regulatory regime. Third, as a matter of outcome, a comparative analysis reveals
that regulation in the United Kingdom has encouraged innovation, which runs counter
to the prevailing view that regulation had adverse effects on innovation, whereas in the
IV.

3,
2018),
https://www .tricare.mil/CoveredServices/IsltCovered/ AssistedReproductiveServices
[https://perma.cc/6VVR-D292] ("To be medically necessary means it is appropriate, reasonable, and adequate
for your condition. and combined with natural conception.").
158
See sources cited infra note 160 and accompanying text (discussing the National Academy of Science's
report completed at the request of the FDA).
159
THE NAT'L ACADS. OF SCI., ENG'G & MED., MITOCHONDRIAL REPLACEMENT TECHNIQUES: ETHICAL,
SOCIAL, AND POLICY CONSIDERATIONS (2016) [hereinafter MRT REPORT]. For a summary of the 2016
National Academy of Sciences report, see Adashi & Cohen, supra note 143, at 450 Box 2.
160
MRT REPORT, supra note 159, at ix, 2 ("The proposed investigation and potential clinical use of
mitochondrial replacement techniques (MRT) raises a novel collection of ethical, social, and policy issues. At
the request of the U.S. Food and Drug Administration (FDA), the National Academies of Sciences,
Engineering, and Medicine convened a committee with diverse interdisciplinary expertise and a range of
backgrounds to examine and analyze these issues, make recommendations regarding whether and how to go
forward with MRT, and elaborate principles for initial clinical investigations involving these novel techniques
for avoiding some types of inherited mitochondrial DNA (mtDNA) diseases.").
161
Id. at xv-xi.
162
See Richard A. Bierschbach & Stephanos Bibas, Notice- and- Comment Sentencing, 97 MINN. L. REV. 1, 20
(2012); Seifter, supra note 19, at 1308; Evan J. Criddle, When Delegation Begets Domination: Due Process
of Administrative Lawmaking, 46 GA. L. REV. 117, 123 (2011); Rose-Ackerman, supra note 21, at 439; Seifter,
supra note 19, at 1308.
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United States, regulation has operated to the detriment of innovation in the realm of
advanced assisted reproductive technologies. 163
There are a number of aspects of American regulation of ART that defy the
traditional administrative law goals. Transparency is one of the goals of administrative
law that often surfaces in the literature analyzing the actions of administrative
agencies. 164 For example, the Administrative Procedure Act contains statutory
requirements including "notice-and-comment" mlemaking procedures which operate to
provide democratic inputs into the administrative process. 165 To the extent that one of
the goals of administrative law and constitutional law is to "reconcile established legal
traditions with pragmatic efforts to better balance expertise and accountability with the
protection of individual rights," the current system has led to a lack of expertise,
accountability, and protection of individual rights in the realm of advanced assisted
reproductive technology innovation. 166
While administrative law, especially in the United States, purports to address
the detailed implementation of the legislature's directives, administrative law "also
concerns the democratic legitimacy of government policymaking. A fair and open
policymaking process helps democratic citizens hold modem government accountable
in the face of demands for delegation and regulation, both within and beyond the
state." 167 Yet, as noted in parts II and III supra, a large piece of the "[f]air and open
policymaking process" is missing in the regulation of ART in the United States. 168
Even analyses of the federal administrative state that do not use the term
"democratic deficit" describe the federal administrative state using characteristics that
are similar to those that exist in countries with democratic deficits. For example, Nina
Mendelson notes that there is an opaqueness to the operation of administrative agency
decision-making and that this " .. .lack of adequate transparency has significant adverse
consequences, both for the appropriateness of presidential influence and for the
legitimacy of agency decision making." 169 The lack of transparency, as it relates to
European Union decision-making, has often surfaced in criticisms of the European
Union. 170 Similarly, from a domestic perspective, a lack of transparency may lead to a
concern that agency actions suffer from a lack of "legitimacy." 17 1 In turn, a lack of
legitimacy can also lead to a lack of accountability as, the more difficult it is to see what
163
See Marchant, supra note 20, at 256 ("Administrative agencies are required to partake in extensive,
procedurally time-consuming activities geared toward public participation and judicial review before setting
final rules - a lengthy,time-consuming effort that is not in harmony with the speed of innovation." (citation
omitted)).
164
See Farber & O'Connell, supra note 19,at 1337.
165
See 5 U.S.C. § 553 (2012); see also Thomas 0. Sargentich, The Critique of Active Judicial Review of
Administrative Agencies: A Reevaluation, 49 ADMIN. L. REV. 599,638 (1997) (highlighting "the transparency
of notice-and-comment rulemaking process "); Seifter,supra note 19,at 1308 ("As the thousands ofregulations
promulgated each year 'wield[] vast power and touch[] almost every aspect of daily life,' the notice-and
comment process under section 553 of the Administrative Procedure Act (APA)--the most well-known and
heralded form of administrative participation,in which interested persons may comment on proposed rules-
has been celebrated as 'a crucial way to ensure that agency decisions are legitimate,accountable,and just."'
(citations omitted)).
166
See Rose-Ackerman, supra note 21, at 439. For more on the concept of "expertise " in administrative law
and the idea that agencies embody subject-specific expertise over the fields that they regulate, see Seifter,
supra note 19,at 1325-29.
167
See Rose-Ackerman, supra note 21,at 436.
16s

Id.

Mendelson, supra note 40,at 1159.
See supra Part III.B.
17 1
See Bierschbach & Bibas,supra note 162,at 20; Mendelson, supra note 40,at 1159.
169

170
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has influenced a decision, the more difficult it is to hold an actor (or actors)
accountable. 172 In sum, analyses of the democratic deficit correspond to analyses of the
extent to which the goals of administrative law are actually being carried out in the day
to-day operation of the administrative state.
The American democratic deficit in ART innovation is also significant because
without it, it is possible that there is less of a "check" on political concerns that might
affect an administrative agency's decision-making. 173 The impact of policy (or politics)
on regulatory decision-making is an issue that is salient in many scientific areas beyond
ART. 174 There is a concern about "political manipulation of scientific research." 175
Specifically, the fear is that "political views submerged in the process of executive
supervision may work themselves out through pressure on an agency to skew its
scientific or technical findings." 176
In the realm of FDA regulation, the regulatory history of Plan B, which
spanned across two Presidential administrations, revealed the extent to which political
pressure could affect regulatory decisions, especially regulatory decisions that are
supposed to be made on the basis of safety and efficacy . 177 Plan B, an emergency
contraceptive that was previously a prescription drug, was accompanied by substantial
data indicating its safety and effectiveness (along with that of its generic drug
equivalents), coupled with its suitability for designation as an over-the-counter, instead
of a prescription dmg. 178 There were many aspects of the FDA's 12-year process of
converting "Plan B and its generic equivalents" from prescription to over-the-counter
status that indicated the influence of politics over scientific decision-making, including
the FDA Commissioner's statement that the FDA would not act in accordance with
scientific evidence indicating that the drug "should be approved for nonprescription use
for all females of child-bearing potential" in the "first time the Secretary of HHS had
ever overruled an FDA decision on an OTC switch." 179 Nonetheless, in a multi-year
regulatory process, accompanied by a U.S. Government Accountability Office ("GAO")
report (at the behest of members of Congress concerned about the influence of politics
over the regulatory process), the purposeful inclusion of individuals with anti-abortion
172
See Bierschbach & Bibas, supra note 162, at 20 ("A central concept [in administrative law] is participation,
the idea that citizens should have some input into agency decisions. Public participation, of course, is not the
only way to check agency abuses. But it is a crucial way to ensure that agency decisions are legitimate,
accountable, and just. [It also] blend[s] democracy with agency expertise and judicial oversight [along with]
legitimacy and accountability concerns."); Mendelson, supra note 40, at 1159.
173
Mendelson, supra note 40, at 1155.
174
See RESCUING SCIENCE FROM POLITICS: REGULATION AND IBE DISTORTION OF SCIENTIFIC RESEARCH 28197 (Wendy Wagner & Rena Steinzor, eds. 2016); Evan J. Criddle, Chevron's Consensus, 88 B.U. L. REV.
1271, 1287-88 (2008).
175
Mendelson, supra note 40, at 1143.
176 Id.
at 1144.
177
See Lisa Heinzerling, The FDA 's Plan B Fiasco: Lessons for Administrative Law, 102 GEO. L. J. 927, 93839 (2014) ("Twelve years passed between the petition of private citizens and public health and medical
organizations to the FD A to approve nonprescription status for levonorgestrel-based emergency
contraceptives and a court order that the FD A do so. . . . Much happened during this time . . . [T] he FD A passed
through two different presidential administrations. Through it all, the FDA remained steadfast on one point: it
would not, despite all of the scientific evidence indicating it was the right thing to do, allow unrestricted access
to all levonorgestrel-based emergency contraception.").
178
Id.; see Kathryn A Watts, Controlling Presidential Control, 114 MICH. L. REV. 683, 708 (2016) (providing
the statement of FDA Commissioner Hamburg: "[i]t is our responsibility at FDA to approve drugs that are
safe and effective for their intended use based on the scientific evidence").
179
Heinzerling, supra note 177, at 947-48; Gardiner Harris, Morning After Pill Is Cleared for Wider Sales,
N.Y. TIMES, Aug. 24, 2006, at A l .
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perspectives on an FDA Advisory Committee, the resignations of multiple career FDA
officials, and federal litigation, it became evident that the FDA' s decision to not approve
the designation of Plan B and similar drugs as an over-the counter-medicine was driven
by political considerations, including the influence of the "White House and
'constituents who would be very unhappy with ... an over-the-counter Plan B."" 180 The
analysis of these actions also emphasized the "clandestine" attempts of the Executive
Branch to influence the FDA and the lack of transparency attributed to many FDA
decisions and processes. 18 1 While Plan B was eventually approved for over-the-counter
use, the FDA's inclusion of political views in the regulatory process led to significant
concern over the independence of the agency and the legitimacy of its decisions. 182
While the American federal government has had little response to the American
democratic deficit in ART innovation, the states have responded in connection to
research issues that often implicate issues related to ART, such as embryo destruction.
The destruction of embryos in connection with research related to embryonic stem cells
has led to significant controversy surrounding ART and stem cell research in the United
States. 183
Analyses of decision-making in the states have also focused on the existence
of the "democratic deficit." 184 Those analyses have found that a "democratic deficit"
also exists in the states, but states are seen as being more responsive to citizen requests
simply by virtue of the fact that in some states, citizens can participate in referenda and
ballot initiatives. 185 Additional analyses have also found that in spite of the "democratic
180
Naomi Cahn & June Carbone, Family Classes: Rethinking Contraceptive Choice, 20 U. FLA. J.L. & PuB.
POL'Y 361, 382 (2009); Watts, supra note 178, at 708; Alastair J.J. Wood et al.,A Sad Day for Science at the
FDA, 353 N. ENG. J. MED. 1197, 1197-98 (2005); see Heinzerling, supra note 177, at 930-58; see also
Tummino v. Torti, 603 F. Supp. 2d 519, 523-24, 544-45, 548 (E.D.N.Y. 2009) ("While it may have been
rational for the FDA to consider adolescent cognitive development in its evaluation of Plan B as an OTC drug,
plaintiffs have presented unrebutted evidence that the FDA's focus on these behavioral concerns stemmed
from political pressure rather than permissible health and safety concerns.").
181
Cahn & Carbone supra note 180,at 381-82; Harris,supra note 179; Watts,supra note 178,at 710-11.
182
See Watts, supra note 178, at 709 ("Not surprisingly, controversy quickly empted over what the media
described as Sebelius's 'unprecedented' decision to override the FDA's science-based findings."); see Alastair
J.J. Wood et al.,The Politics of Emergency Contraception, 366 N. ENG. J. MED. 101,101-102 (2005) ("[W]e
called attention to the damage that the FDA was doing- both to its reputation as an impartial regulatory agency
that made decisions on the basis of science,insulated from politics,and potentially to women's health.");.
183
See Sherley v. Sebelius, 689 F.3d 776, 779 (D.C. 2012) (determining whether federal funding should be
provided to "research projects directly involving the destruction of a human embryo and projects using
embryonic stem cells derived from an earlier destruction"); see also Carbone & Cahn,supra note 180,at 1016
("The status of embryos, which involves profound religious and philosophical differences and which has
become the subject of entrenched political differences over the course of the abortion fight,lies at the heart of
these developments."); Jennifer L. Enmon,Stem Cell Research: Is the Law Preventing Progress?, 2002 UTAH
L. REV. 621, 637-42 (2002) (discussing the debate over the personhood of IVF clinics' excess frozen
embryos); Sonia M. Suter,In Vitro Gametogenesis: Just Another Way to Have a Baby?, 3 J.L. & BIOSCIENCES
87, 116-18 (2016) (discussing the issue of embryo destruction in the context of another form of assisted
reproductive technology, in vitro gametogenesis).
184
See Future of American Federalism, supra note 43,at 1112 ("Although the United States has not generally
been thought to suffer from the same sort of 'democratic deficit' that haunts European discourse, we are
experiencing profound frustration with gridlocked and nonresponsive government in Washington,reflected in
the precipitous decline in public trust in national governing institutions.").
185
Miriam Seifter, Further from the People? The Puzzle of State Administration, 93 N.Y.U. L. REV. 107,14647 (2018) ("[S]cholars,courts,and policymakers . . . tend to agree that states are closer to the people in some
way that matters. In particular,the traditional praise for proximity suggests that it makes state governments
more responsive to their constituents' desires or deters abuses of state power, or both." (citations omitted));
see The President, Executive Order No. 13132, Federalism (Aug. 4, 1999), 64 Fed. Reg. 43,255, 43,255-56
(Section 2. "Fundamental Federalism Principles[:] In formulating and implementing policies that have
federalism implications, agencies shall be guided by the following fundamental federalism principles: (a)
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deficits" that exist in the state levels, many state legislators are responsive to citizen
concerns, albeit with certain biases. 186
The article observes that the process for approving mitochondrial transfer is
swifter (and more concrete) in the United Kingdom than in the United States because in
the U.K., the agency responsible for drafting regulations related to the issue conducted
a public consultation regarding the scientific and ethical issues surrounding the
procedure. 187 In contrast, the United States has avoided using the standard administrative
legal process and public consultations in general when new ART techniques are at
issue. 188 While this approach led to innovation in ART in the past, as traditional ART
developed during the use of a minimally restrictive governance framework, the same
has not occurred as it relates to ART techniques involving inheritable genetic
modifications in the United States. 189 While there has been an ongoing global discussion
of the impacts of germline editing and a robust public discussion in the United Kingdom
of both the impacts of heritable genetic modifications and ART in general, the American
experience has been marked by a more limited national conversation regarding the
impacts of ART and heritable genetic modifications. 190 The national conversation has
largely been limited to a National Academy of Sciences report and conversations among
employees of the Executive Branch, which includes the FDA, and has failed to include
the larger American public. 19 1 Further, funding restrictions implemented by Congress
Federalism is rooted in the belief that issues that are not national in scope or significance are most appropriately
addressed by the level of govermuent closest to the people. . . . (d) The people of the States are free, subject
only to restrictions in the Constitution itself or in constitutionally authorized Acts of Congress, to define the
moral, political, and legal character of their lives. (e) The Framers recognized that the States possess unique
authorities, qualities, and abilities to meet the needs of the people and should function as laboratories of
democracy.").
186
See Micah Gell-Redman et al., It's All About Race: How State Legislators Respond to Immigrant
Constituents, 71 POL. RES. Q. 517, 527-28 (2018); Kim Q. Hill & Jan E. Leighley, The Policy Consequences
of Class Bias in State Electorates, 36 AM. J. POL. SCI. 351,363 (1992); but see Seifter,supra note 185,at 14650.
187
2013 ANNUAL REPORT, supra note 83, at 4 ("The dialogue, entitled 'Medical Frontiers: debating
mitochondrial replacement',was carried out over a period of six months,where we took the public temperature
on this important and emotive issue. Our consultation showed broad support for mitochondrial replacement
being made available to families with serious inherited mitochondrial diseases, provided the techniques are
safe enough to use in the clinic and are well regulated.").
188
See supra Part IILB. l ; see also Subterranean Regulation, supra note 5,at 1241-45 (2018) (discussing the
FDA's issuance of Untitled Letters to providers of forms of assisted reproductive technology involving genetic
modifications).
189
See supra Part III; see also Lars Noah,Assisted Reproductive Technologies and the Pitfalls of Unregulated
Biomedica!Innovation, 55 FLA. L. REV. 603,617-18 (2003) ("Unlike other medical technologies,ARTs arrive
on the scene with little or no rigorous testing of their safety and effectiveness.").
190
See Jordan Paradise, U.S. Regulatory Challenges for Gene Editing, 13 SCITECH LAWYER 10, 11 (2016);
International Summit on Human Gene Editing, NAT'L ACADS. OF SCI., ENG'G, & MED.,
http://nationalacademies.org/gene-editing/Gene-Edit-Summit [https://perma.cc/9 JUF-7 4CX] ("A major
component of the National Academy of Sciences and the National Academy of Medicine's Human Gene
Editing Initiative is an international summit that took place December 1-3,2015,in Washington, D.C. Co
hosted with the Chinese Academy of Sciences and the U.K.'s Royal Society, the summit convened experts
from around the world to discuss the scientific, ethical,and governance issues associated with human gene
editing research."); Second International Summit on Human Gene Editing, NAT'L ACADS. OF SCI.,ENG'G,&
MED.,http://www.nationalacademies.org/gene-editing/2nd_summit [https://perma.cc/P6C4- KXZ5].
191
See sources cited supra notes 148-50 and accompanying text (discussing the FDA's approach to political
and social concerns that "have the potential to affect regulatory decisions."); see also NAT'L ACADS. OF SCIS.,
ENG. & MED., MITOCHONDRIAL REPLACEMENT TECHNIQUES: ETHICAL, SOCIAL, AND POLICY
CONSIDERATIONS 150 (2016). For more on the study approach,see id. at 3,24; see also R. Alta Charo,Dealing
with Dolly: Cloning and the National Bioethics Advisory Commission, 38 JURIMETRICS J. 11, 11-14 (1997)
(discussing the roles of "public bioethics commissions," including presidential bioethics commissions); M.
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have created an environment in which, even if the hurdle created by the actions of those
employed by administrative agencies was removed, these techniques would still face
significant obstacles to federal approval in the U.S. 192
As a matter of outcome, there are also practical implications to the United
States' democratic deficit in ART, which has culminated in a restrictive regime that
hinders access to advanced assisted reproductive technologies. As seen in instances of
cytoplasmic transfer 193 in the United States, when the technique is not available in the
United States, those with economic means are able to obtain it abroad, like the patients
of the aforementioned Dr. Zhang who traveled to Mexico in order to obtain
mitochondrial transfer from a U.S.-based physician in contravention of federal
restrictions. 194 This response raises the issue of "reproductive tourism." 195 Many
scholars have noted that FDA approval is often a precursor to insurance coverage of a
treatment. 196 Further, this is especially relevant in the realm of ART where a small
number of states mandate coverage of ART services. 197 Thus, to the extent that the FDA
fails (or refuses) to approve these techniques in the United States, it could contribute to
the gap in healthcare between those who are well-off, and can pursue treatments without

Cathleen Kaveny,Rhetoric, Public Reason and Bioethics: The President's Council on Bioethics and Human
Cloning,20 J.L. & POL. 489, 491-94 (2004); John P. Holdren,Note on Genome Editing, THE WHIIB HOUSE
OFFICE (May 26, 2015), https://obamawhitehouse.archives.gov/blog/2015/05/26/note-genome-editing
[https://perma.cc/P4PD-RE7Z] ("The White House fully supports a robust review of the ethical issues
associated with using gene-editing technology to alter the human germline. The Administration believes that
altering the human germline for clinical purposes is a line that should not be crossed at this time.").
192
See Rob Stein,Babies With Genes From Three People Could Be Ethical, Panel Says, NPR (Feb. 3,2016),
http://www.npr.org/sections/health-shots/2016/02/03/465319186/babies-with-genes-from-three-people
could-be-ethical-panel-says [https://perma.cc/T4DZ-AX K7] (discussing the National Academies of Sciences,
Engineering and Medicine report on cytoplasmic transfer); Statement on NIH Funding of Research Using
Gene- Editing Technologies in Human Embryos, NAT'L INST. OF HEALTH (Apr. 29, 2015),
https://www.nih.gov/about-nih/who-we-are/nih-director/statements/statement-nih-fuuding-research-using
gene-editing-technologies-human-embryos [https://perma.cc/7 KGM-AHV3] (indicating that the NIH will not
fund any use of gene-editing technologies in human embryos."). While gene editing and mitochondrial
transfer are different techniques and research involving mitochondrial transfer is arguably further ahead due
to its actual clinical use in the U.K. (and the use of it by U.S. doctors abroad), the social and ethical issues
posed by genetic modification exist for both technologies.
193
Ooplasmic/Cytoplasmic Transfer, C1R. FOR GENETICS & Soc'Y,https://www.geneticsandsociety.org/
internal-content/ooplasmiccytoplasmic-transfer [https://perma.cc/UB G9-RP22] (defining cytoplasmic
transfer as "an experimental fertility technique that involves injecting a small amount of ooplasm from eggs
of fertile women into eggs of women whose fertility is compromised. The modified egg is then fertilized with
sperm and implanted in the uterus of the woman attempting to achieve pregnancy.").
194
See Zhang, supra note 116 and accompanying text.
195
See Lisa C. Ikemoto,Reproductive Tourism: Equality Concerns in the Global Market for Fertility Services,
27 J. L. & INEQUALITY 277, 277-79 (2009) (discussing the practice of "reproductive tourism," and those who
travel to access fertility treatments); Kimberly M. Mutcherson, Welcome to the Wild West: Protecting Access
to Cross Border Fertility Care in the United States, 22 CORNELL J. L. & PUB. POL'Y 349, 349-50 (2012)
(discussing "cross border fertility care").
196
See, e.g., Rachel E. Sachs, De/inking Reimbursement, 102 MINN. L. REV. 2307, 2309, 2314-21 (2018)
("Although there is not always perfect agreement between the set of FDA-approved drugs and the drugs payers
are required to cover,in general there is significant overlap. Particularly for public payers,this robust coverage
of prescription drugs is required by federal law. Although private payers are often less constrained, many of
them provide similarly comprehensive prescription drug coverage pursuant to federal and state laws.").
197
See King,supra note 27,at 313 n.142 (discussing access to assisted reproductive technologies,disparities
in access to ART,and states that mandate insurance coverage of ART); Falloon & Rosoff,supra note 157,at
63-64 (discussing barriers to access to assisted reproductive technology that exist even with insurance
coverage).
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insurance coverage, and those who cannot. 198 As such, under this democratic deficit,
disparities continue to exist not only with respect to the experience of U.S. patients as
compared to those in other countries, but also with respect to experiences of patients
within the United States, where some patients will be able to travel to access innovations
in ART and others will not. 199
States have also enacted legislation related to embryonic stem cell research,
with some states encouraging it, and others banning it.200 As a matter of funding, in
response to actions at the federal level that have precluded innovation by limiting the
availability of research funding, some states, like California, have used representative
democracy to identify state goals for innovation, such as the California Institute for
Regenerative Medicine which was created after a referendum201 and New York's Empire
State Stem Cell Trust Fund which was created through State Finance Law. 202 State
coverage of stem cell research is relevant because it implies that there was some
democratic input into the funding process at the state level whereas at the national level,
the Executive and Legislative Branches (through budget riders) tend to exercise control
over research funding involving techniques that are accompanied by ethical
controversy.203 The New York Stem Cell Fund has contributed to research related to
mitochondrial transfer.204 In turn, this state-funded research has contributed to the
international discourse on ART techniques involving inheritable modifications. 205 In
other words, where there is limited federal funding, the private sector and states may
respond in furtherance of innovation.
198
See Judith F. Daar, Accessing Reproductive Technologies: Invisible Barriers, Indelible Harms, 23
BERKELEY J. GENDER L. & JUST. 18, 22, 31-32, 36-39 (2008) (discussing political, socioeconomic, and racial
barriers to accessing assistive reproductive treatment).
199
See I. Glenn Cohen, Circumvention Tourism, 97 CORNELL L. REV. 1309, 1311-12, 1323-26 (2012)
(discussing "medical tourism" in the context of assisted reproductive technology, in addition to
"circumvention tourism," a subset of medical tourism).
200
Enmon, supra note 183, at 641-47 (discussing various state statutes affecting embryonic stem cell research).
201
About CIRM, CAL. INST. FOR REGENERATIVE MED. (2018), https://www.cirm.ca.gov/
[https://perma.cc/QG7T-F5XH].
202
Frequently Asked Questions About NYSTEM, N.Y. STATE, https://stemcell.ny.gov/node/191
[https://perma.cc/Y3TX-9LEH]. For more on state stem cell initiatives, see CONGRESSIONAL RESEARCH
SERV.,
STEM
CELL
RESEARCH:
STATE
INITIATIVES
2-8
(2006),
https://stemcells.nih.gov/staticresources/research/GW-State-Funding.pdf; State Initiatives for Stem Cell
Research,
NAT'L
INST.
OF
HEALTH,
https://stemcells.nih.gov/research/state-research.htm
[https://perma.cc/CS82-9FKJ].
203
See Sebelius, 689 F.3d at 780 (discussing the role of Presidents George W. Bush and Barack Obama in
providing guidance to the National Institutes of Health on the funding of stem cell research); see also
Calandrillo & Deliganis, supra note 77, at 313.
204
See Jeff Lyon, Sanctioned UK Trial of Mitochondrial Transfer Nears, 317 JAMA 462, 463 (2017) ("The
HFEA hesitated last summer when maj or players in the drive to bring MRT to fruition published work that
included some qualms. The first article last June in Cell Stem Cell described an in vitro experiment in which
Dieter Egli, PhD, and his colleagues at the New York Stem Cell Foundation sought to determine what happens
to the minute amount of maternal mtDNA that inevitably hitches a ride when researchers create an embryo
with the mother's nDNA and the donor's healthy mtDNA.").
205
Id. Additionally, just as states have provided funding of stem cell research in the absence of governmental
funding, private organizations (including professional organizations) have also provided funding for assisted
reproductive technology research. See Am. Soc. for Reproductive Med., American Society for Reproductive
Medicine Announces Major Research Initiative- Creation of the ASRM Research Institute, a $10 Million
Startup Investment for the Future of Reproductive Medicine, ASRM BULLETIN (Jun. 12. 2018),
https://www.asrm.org/news-and-publications/news-and-research/press-releases-and-bulletins/american
society-for-reproductive-medicine-annonnces-major-researchinitiative/? _ga=2.228771932. l l 4722499.1545121639-l 132316020.1545121639
[https://perma.cc/CAA28R5L ].
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The U.S. experience with ART, primarily at the federal level, highlights the
lack of transparency and public participation in the administrative process even though
the administrative legal process was structured to further these goals. 206 As a result,
states are making up for the lack of public participation in federal administrative law. 207
The next section crafts solutions based on a number of disciplines, notably
administrative law and health law, to the American democratic deficit in ART
innovation.
V.
ADAPTING THE TOOLS OF ADMINISTRATIVE LAW TO MINIMIZE
THE U.S. DEMOCRATIC DEFICIT IN ASSISTED REPRODUCTIVE
TECHNOLOGY INNOVATION
The solutions in this section could minimize the American democratic deficit
in ART and also hasten the implementation of forms of ART involving genetic
modification. These recommendations draw on scholarship in administrative law and
examples of successful approaches, including the UK's experience with mitochondrial
transfer and state experiences with stem cell research funding and legislation. Part A
examines and critiques the possibility of an independent federal agency in the United
States that would regulate ART use, whereas parts B-D examine the UK's five-strand
public discourse on mitochondrial transfer and methods of adapting public discourse
into the American administrative state.
AN INDEPENDENT FEDERAL AGENCY IN THE U.S.
While other scholars have argued for an independent federal agency
to regulate ART, this article does not advocate for that approach.208 Many of the scholars
who do advocate for an independent federal agency build on the example of the
HFEA.209 Yet, despite the similarities between the United States and the United
Kingdom, many differences between the two would make the creation of such an
independent federal agency addressing ART both unlikely and unfeasible. First,
religious opposition to ART and the medical industry's general opposition to increased
regulation would make it difficult to create such an agency.210 Second, logistically, even
A.

See Bierschbach & Bibas, supra note 162, at 23 ("Participation . . . enhances the soundness of agency
decisions by improving the quality and variety of the information an agency considers, whether empirical or
related to the public's preferences. It improves accountability by obligating agencies to justify their actions
publicly . . .It increases public trust and educates citizens in government affairs, creating feedback loops
between agencies and citizens. And,. . . it bolsters agency decision-making's democratic pedigree." (citations
omitted)); Marchant,supra note 20,at 256.
207
See Nina Mendelson, A Presumption Against Agency Preemption, 102 NW. U. L. REV. 695, 709 (2008)
("Second, federalism, including a state's enactment of its own laws,also may stimulate citizen participation in
self-governance,on the theory that it is easier to participate at a level of government closer to one's home.");
but see Frank Cross,The Folly of Federalism, 24 CARDOZO L. REV. 1,1-2 (2002) (suggesting that "federalist"
values are really values of localism). While much of the administrative law scholarship focuses on
administrative law at the national level, states also have administrative agencies. For more on state
participation in the federal administrative law process and the implementation of federal programs, see
generally, Seifter, supra note 155. For more on the operation of administrative law at the state level, see
Michael Asimow, Contested Issues in Contested Cases: Adjudication Under the 2010 Model State
Administrative Procedure Act, 20 WIDENER L.J. 707, 707-13 (2011); Seifter, supra note 185, at 131-48;
Michael Asimow, The Influence of the Federal Administrative Procedure Act on California's New
Administrative Procedure Act, 32 TuLSA L. J. 297, 298-303 (1996); Seifter,supra note 185,at 131-48..
208
See King,supra note 27,at 169-70.
209
See id. at 169 (referring to "the HFEA indications approach ").
210
Robert Gatter, Faith, Confidence, and Health Care: Fostering Trust in Medicine Through Law, 39 WAKE
FOREST L. REV. 395,440 (2004); William M. Sage & David A Hyman,Combating Antimicrobial Resistance:
206
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if such an agency was created, significant effort would likely have to be exerted in order
to figure out how that agency and the FDA, which has been regulating ART involving
genetic modification and the drugs and devices used in ART treatments would share
jurisdiction, if at all. Additionally, if funding restrictions imposed by Congressional
budget riders continued to exist, then an HFEA-like agency would have to decide how
the National Institutes of Health would fit into the regulatory framework. Further, an
independent federal agency would still remain subject to political pressure and
budgetary control by Congress and the President.2 11 Additionally, while Congress could
introduce an act to seize power from the states, who have regulated (or failed to regulate,
depending on one's point of view) ART, giving the federal govermnent more power
over reproductive issues (and by implication, reproductive rights and the practice of
medicine), this in general does not resolve the issue of who should be regulating ART.
Additionally, from the perspective of strengthening reproductive rights (or maintaining
the status quo), is likely undesirable. 2 12 Beyond that, the myriad of issues surrounding
ART, especially in a country that has failed to have a national public discourse on
traditional ART, would not be resolved by the creation of an HFEA-like agency.
B.

ADAPTING THE UK'S PUBLIC CONSULTATION ON ASSISTED REPRODUCTIVE
TECHNOLOGY TO THE U.S. REGULATORY REGIME

Many aspects of the UK's public consultation on mitochondrial transfer would
fit into the United States' existing federal regulatory framework governing ART. Just as
notice-and-comment rulemaking can improve public participation in the administrative
process, so can other methods of promoting the inclusion of public views in the agency
regulatory process.2 13 In fact, many of the aspects of the UK's public consultation on
mitochondrial transfer are similar to actions that the HHS has already undertaken for
other issues.2 14
For example, when determining the meaning of essential health benefits, the
HHS allowed individual states to set that benchmark. 2 15 Before issuing the document
that announced this decision, HHS undertook a number of methods of outreach with
Regulatory Strategies and Institutional Capacity, 84 TuL. L. REV. 781, 815 (2010) (discussing self-regulation
in healthcare); but see John A. Robertson, Assisted Reproductive Technology and the Family, 47 HASTINGS
L.J. 911, 920 (1996) (noting that the American Society for Reproductive Medicine would be amenable to an
HFEA-like agency that would license and inspect fertility clinics, whereas the author, Professor John
Robertson, is skeptical of the creation of such an agency); Robertson, supra note 24, at 1035-36 ("With
adequate peer involvement, more explicit legal controls, such as the national licensing authority suggested in
the Warnock Report, need not take root in American soil.").
211
Kirti Dada & Richard L. Revesz, Deconstructing Independent Agencies (and Executive Agencies), 98
CORNELL L. REV. 769, 808, 816 (2013); Neal Devins, Regulating of Governmental Agencies Through
Limitations Riders, 1987 DUK.E L. J. 456, 461 (discussing "appropriations as oversight").
212
See King, supra note 27, at 173 (detailing the "five main functions" of a proposed "national independent
regulatory body . . . which would include at least two functions that would infringe on the practice of medicine:
" l ) establish a licensing system for ART clinics; 2) establish procedural guidelines and regulations for ART
practice; . . . 5) in the case that proven risks outweigh the benefits for certain procedures, regulate the use of
PGS for certain indications using the novel balancing framework proposed above."); see also Cahn & Carbone,
supra note 180, at 380 (discussing "how politics at the national level can affect access to reproductive rights").
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Bierschbach & Bibas, supra note 162, at 20.
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See HHS Agencies & Offices, U.S. DEP'T OF HEALTH & HUMAN SERVS. (Oct. 27, 2015),
https://www.hhs.gov/about/agencies/hhs-agencies-and-offices/index.html
[https://perma.cc/S32Y-UK7V]
("HHS has 11 operating divisions, including eight agencies in the U.S. Public Health Service and three human
services agencies."); id. (noting that the FDA is an operating division within the U.S. Department of Health
and Human Services).
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states and other stakeholders, including the public with whom the agency interacted
through "a series of 'listening sessions. "' 2 16 Professors Bagley and Levy note that HHS
had no obligation to undertake such an inclusive approach under the Administrative
Procedure Act's notice-and-comment requirements.2 17 Yet, such an inclusive process
would greatly improve the regulation of advanced assisted reproductive technologies in
the United States. Granted, the example of deciding what would be included in the term
"minimum essential health benefits" is not a perfect parallel to ART innovation. While
it is likely that ethical and political views on reproduction and women's health surfaced,
those ethical views were not the same as those involved in regulating traditional ART
and advanced assisted reproductive technologies. 2 18 Nonetheless, the format of these
"listening sessions" could be used in public discourse related to a number of other
health-related issues, including ART.
The listening sessions held by HHS are similar to the second and third strands
of the UK's public consultation, which included face-to-face interviews with members
of the public.2 19 As it is, U.S. administrative agencies already conduct "public meetings"
in which they explain regulatory decisions; therefore, the structure for something
analogous to the second strand of the UK's public consultation already exists.
Additionally, agencies are staffed by scientific (and technical staff). Thus, agencies
already employ individuals who, like those who provided explanations to members of
the public of the science underlying mitochondrial transfer in the first strand of the UK
public consultation, could explain to the American public the techniques involved in
mitochondrial transfer. 220 The FDA, for example, already has a "Grand Rounds"
program in which FDA scientists "present[] on a key public health challenge and how
FDA is applying science to its regulatory activities." 22 1 The FDA could expand this
Grand Rounds Program and expand its format into the agency's public meetings, were
it to participate in a public discourse on mitochondrial transfer.
Another option is to increase the visibility of the array of ethical and social
viewpoints on ART in order to address the current situation in which the positions of
politicians have been serving as proxies for the viewpoints of members of the American
public. The current point of reference in the U.S. for ethical issues related to new forms
of ART is driven by the feelings or beliefs of politicians and employees in the federal
legislative and executive branches, yet no one has asked the American public whether it
has an opinion on forthcoming medical innovations and their perrnissibility. 222 These
216
217
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Id. ("The agency had no obligation to do any of this public outreach. Without informing anyone of its

thinking, HHS could simply have issued a notice of proposed mlemaking annonncing the benchmark
approach. After receiving comments and issuing a final rule,HHS would then have complied with all of the
APA's notice-and-comment requirements."); id. at 456 (noting that "agencies do not have to solicit feedback
on guidance documents.").
218
Cf Burwell v. Hobby Lobby,573 U.S. 682 (2014). Thus,while ethical views may not have prevented the
inclusion of contraception in minimum essential health benefits at the level of the administrative agency's
decision making, the ethical views, which would be religious views in the Hobby Lobby case, of those who
would be subsidizing the insurance plans required to have minimum essential health benefits are entitled to a
certain amonnt of exemption or waiver by the federal government.
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political feelings or beliefs manifest not only through public statements, but also
regulatory actions that have not been subject to judicial review, such as funding
restrictions, budget riders and non-interpretive documents issued by administrative
agencies.223 As such, another option could be to use mlemaking to address the issue of
federal regulation of ART using a rule instead of informal documents, as doing so could
also facilitate the deliberative public process that is currently missing in the federal
regulation of ART.224
In 2016, Professor Barbara Evans wrote that "[i]t is time to insist on evidence
based bioethics."225 Again, the UK's public consultation could serve as a model for the
United States. For example, the UK asked members of the public what their views were
on the ethical considerations related to mitochondrial transfer and then tracked whether
their views changed after the concept was further explained to them. 226 Implementing
something similar in the United States would be a way to institute evidence-based
bioethics.227 Considering the role of states, outside of the bioethics literature other
professors have noted that "experimentation may help clarify the ideological space." 228
In the area of stem cell research, state involvement has already created an experimental
ideological space where state laws and funding decisions are proxies for the views of
the public.229 At the federal level, using patient focus groups, for example, as the UK
did in the fifth strand of their public consultation, would allow members of the public to
provide input on the "moral, ethical, and social policy issues related to genetic
modification of eggs and embryos ... that . . . have the potential to affect regulatory
decisions.230
C.
GREATER DISCLOSURE: SEPARATING SCIENTIFIC CONCERNS FROM POLITICAL
AND ETHICAL CONCERNS

Many scholars have written in favor of more disclosure and transparency
within the administrative law and health law literatures.23 1 Professor Nina Mendelson,
["prais[ed] the 'thoughtful work' of the panel and said the agency would be 'reviewing' the recommendations
of the 2016 Institute of Medicine Panel] . . . [since then] . . . the latest federal budget 'prevents the FDA from
using funds to review applications in which a human embryo is intentionally created or modified to include'
changes that could be passed down to future generations . . . any such research 'cannot be performed in the
United States' at this time"]."] . . . [This] would cause 'undue delays' in his research, he added that he hoped
it wouldn't permanently 'necessarily halt the efforts. "' ).
223
See FDA Letter, supra note 119 (noting that the FDA had jurisdiction over the mitochondrial replacement
techniques used by Dr. John Zhang and also noting that, pursuant to the Consolidated Appropriations Act, the
FDA could not use "funds to accept IND submissions for clinical itNestigations that involve 'a human embryo
. . . intentionally created or modified to include a heritable genetic modification. "' ).
224
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domains- for example, when stem cell research first arose as a policy question- experimentation may help
clarify the ideological space."); see id. at 674 n.118 ("Clarifying ideological space may be of value to society,
depending on how that information is put to use. Even if the clarification is not socially valuable, it might still
be valuable to political actors.").
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for example, has argued for greater disclosure of the role of executive supervision in
agency decisions.232 One hope is that greater disclosure of the role of executive or
political pressure in agency decisions might lead to a more deliberative democracy
where agency employees disclose to what extent their views are, as evidenced by for
example, the FDA' s decisions related to the prescription over-the-counter switch of Plan
B, actually based on safety and efficacy and not factors outside of the agency's statutory
mandate, such as political pressure.233 Further, a significant amount of the FDA's
decision-making process occurs outside of the public's view and "documents exchanged
between the FDA and a drug sponsor during the back-and-forth over a new drug
application are not made public, often not even after the application is approved." 234 In
other words, to the extent that political pressures, moral concerns, or social policy views
are being incoiporated into the decision-making process, they should be disclosed. 23 5
This article takes a similar approach as, in the realm of assisted reproduction, scientific
and social concerns often overlap, even though the FDA is an agency that is supposed
to regulate for safety and effectiveness. 236 For example, in the realm of cloning (which
is not an ART, as it does not so much involve reproduction as replication), the FDA
stated that not only did the procedure require an investigational new drug application,
but also that the FDA would not accept any applications due to unresolved safety
concerns, yet the agency did not identify those concerns. 237 In the instance of the FDA's
original failure to approve Plan B for use in all women of childbearing age, the agency
seemed to also muddle social concerns with safety concerns.238 The FDA has undertaken
a similar approach to forms of ART involving genetic modification. For example, with
respect to cytoplasmic transfer, the FDA reportedly told one researcher, who engaged
with them after receiving a letter stating that the technique would require an
investigational new drug application, that the researcher would have to prove that the
technique was safe.23 9 The agency could not, however, tell the researcher what studies

McCuskey, Agency Imprimatur & Health Reform Preemption, 78 OHIO ST. L.J. 1059, 1162 (2017) ("The
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(Mar.
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2018),
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2001, FDA sent a letter to the research community asserting regulatory authority over clinical research using
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genetic material by means other than the union of gamete nuclei. Examples of such genetic material include,
but are not limited to: cell nuclei (for cloning), oocyte nuclei, ooplasm, which contains mitochondria and
genetic material contained in a genetic vector, transferred to gametes or other cells. Any clinical research
involving these techniques would require an IND.").
238
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would be required in order to prove that the technique was safe. 24° Considering the
FD A's statutory mandate, which is to evaluate products for safety and effectiveness, the
agency should be able to articulate to prospective applicants what would satisfy its
interpretation of the safety and effectiveness requirements of its enabling statute. 24 1 Not
doing so causes the public to question "the integrity of the [regulatory] process," and for
those in the medical profession, "[i]t is also likely to mean that both physicians and
patients will wonder whether future drug-approval decisions are based on the evidence
with regard to efficacy and safety or, rather, on, political considerations. How will we
know? How will we find out?" 242
These concerns regarding the integrity of the regulatory process undermine
administrative law's goals of accountability and legitimacy. 243 While the public was able
to ascertain the existence of decision-making outside of the statutory mandate in the
instance of Plan B, it required federal litigation (that included discovery beyond what
the public would have been able to obtain through Freedom of Information Act requests)
and a GAO report.244 The experience of the FDA in regulating other forms of ART
involving genetic modification indicates that it is possible that the FDA continues to
succumb to political and social pressures in the regulatory process, yet the public lacks
an opportunity to ascertain whether that is the case. Increasing the use of deliberative
democracy in the decision-making process would increase the opportunity for the public
to ascertain what underlies the agency's decision-making and also, to the extent that
political or social views are being considered in the regulatory process, create an
environment for a more thorough and fair consideration of social and political views,
with transparency.
In light of the UK's robust analysis of the underlying safety and effectiveness
of mitochondrial transfer, using the UK's five-strand consultation could aid the FDA in
separating its safety analysis from its social analysis.245 Drawing from the UK's analysis
would allow the FDA to categorize exactly which aspects of its regulatory decision
making corresponds to (1) safety, (2) effectiveness, and (3) political, social, and ethical
considerations. For example, the public consultation in the UK revealed that many
individuals' concerns surrounded the safety of the techniques and that "[s]ometimes,
safety concerns become a proxy for concerns about ethical and social issues, which are
often hard to express. On other occasions, support for mitochondria replacement dipped
when the scientific evidence was less clear."246 In the leadup to the approval of
mitochondrial transfer in the United Kingdom, the HFEA conducted multiple reviews
of the scientific and safety issues related to the use of mitochondrial transfer, where it
examined the existing medical literature and current research, including that of U.S.
based scientists.247 The example of the UK's approval of mitochondrial transfer, which
included a safety and scientific review, in addition to a public consultation and an
assessment of social and ethical considerations, indicates that safety and science
. you can never say 'it's safe' until you do it."); see supra note 104 and accompanying text (providing the
similar view of the UK's Chief Medical Officer on the use of mitochondrial transfer in humans).
24
° Connor, supra note 6.
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analyses can be separated from ethical, social, and political concerns. Applying the
lessons of the U.K. 's experience with the approval of mitochondrial transfer, the FDA
should clearly state which aspects of current and forthcoming ART and advanced
assisted reproductive technologies implicate scientific concerns and which aspects
implicate social, political, and ethical considerations.
D.

INCREASING THE ROLE OF THE STATES

States have instituted a number of measures that address the deficit in
deliberative democracy related to stem cell research and ART in the United States.
Increasing the role of the states in the regulation of traditional ART and advanced
assisted reproductive technologies flows naturally from the jurisdiction of states and
their responses to democratic deficits in the regulatory process in the United States to
date. As a jurisdictional matter, states already have historic police powers that empower
them to serve as gatekeepers to the medical profession. 248 Additionally, states have
regimes to compensate citizens for certain harms suffered during medical treatment
through tort regimes that provide for medical malpractice liability. 249 Beyond creating
liability regimes for damages incurred during medical treatment, states have also
instituted regimes that recognize the results of ART use, whether of parentage or leftover
embryos, through family law statutes and court decisions.25° Further, as a matter of
funding, some states fund research that the federal government will not, with an
emphasis on research that involves the destruction of embryos.25 1 At the same time,
states have created statutory regimes that indicate what kind of research they will fund,
with some states funding types of research that Congress would not and other states
creating regimes with restrictions that are very similar to federal limitations.252
Nonetheless, the benefit of these state regimes is that they allow for more democratic
participation by, at the very least, clearly signaling to the public that lawmakers are
undertaking decisions related to these matters.
For those states that do choose to fund research and innovation that has been
stymied by Congress, it could be useful for them to take on a stronger role in the
gathering of information related to innovations in ART or medicine in general. For
example, a common refrain of scientists whose research involves genetic modification
is that society needs to decide whether it is desirable to undertake scientific innovations
that involve inheritable genetic modifications. 253 This is notable not only because it is a
deviation from the often-undertaken effort of scientists and physicians to regulate
themselves, but also because it represents a call by innovators to include societal views
in science.254 Currently, the national government has failed to undertake this
conversation, but states are well-placed to do so as an alternative to the current
regulatory standstill in the absence of discourse, by virtue of their proximity to
citizenry.255 Not only might states want to undertake this consultation on their own, but
248
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the federal government should consider whether it should actively encourage states to
do so, as increasing the participation of states in the regulatory regime might not only
encourage public involvement in the regulatory process, but also allow for
experimentation.256
VI.

CONCLUSION
The article has focused on the American democratic deficit in ART and how
states have made strides in correcting that deficit. For decades, the political discourse
has remained at a standstill as legislators have refused to address questions related to the
ethics of ART, especially those involving germline modification. Furthermore, those
legislators have refused to address those questions through several actions including: (1)
spending restrictions on applications that would involve such processes, (2) refusing to
check administrative agency overreach, in spite of media and literature coverage, and
(3) the disbanding of bioethics commissions.
While ethics certainly matter, the question of whether they should impact
regulatory decision-making, instead of being left to the doctor-patient relationship
(assuming all patient protections such as informed consent and patient protective
bioethics principles exist), is a question for another article.257 Also, to the extent that
there is a concern in the United States as to partisan politics affecting health care,
individual rights, and science more broadly, expanding the use of democratic inputs,
especially as it relates to federal decision-making that implicates reproductive rights,
reproductive healthcare, and ultimately the ability of parents to decide what is best for
their future children, adopting the solutions provided in this article might " ... not only
produce more effective policy but also increase the acceptability of the regulatory
process."258 Doing so would have implications not only for the administrative state, but
also for the American public's impressions of the administrative state and the role of the
federal government in affecting their everyday lives.
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